<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">DcFpztJFq5hgxwCvm6HrXZR</article-id>
      <article-id pub-id-type="other">00017</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010000100017</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09400117</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010000100017</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Anormalidades cardiovasculares e metab&#243;licas em pacientes com a s&#237;ndrome de Berardinelli-Seip</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>R&#234;go</surname>
            <given-names>Antonio Guedes do</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mesquita</surname>
            <given-names>Evandro Tinoco</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Faria</surname>
            <given-names>Carlos Alberto de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>R&#234;go</surname>
            <given-names>Marcel &#193;lvares Guedes do</given-names>
          </name>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baracho</surname>
            <given-names>Maria de F&#225;tima Paiva</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Maria Goretti do Nascimento</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Egito</surname>
            <given-names>Eryvaldo S&#243;crates Tabosa do</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brand&#227;o Neto</surname>
            <given-names>Jos&#233;</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Natal</named-content>
          <named-content content-type="state">Rio Grande do Norte</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal do Rio Grande do Norte</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="city">Natal</named-content>
          <named-content content-type="state">Rio Grande do Norte</named-content>
        </addr-line>
        <institution content-type="orgname">Clinicor</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Niter&#243;i</named-content>
          <named-content content-type="state">Rio de Janeiro</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal Fluminense</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>01</month>
        <year>2010</year>
      </pub-date>
      <volume>94</volume>
      <issue>1</issue>
      <fpage>109</fpage>
      <lpage>118</lpage>
      <history>
        <date date-type="rev-recd">
          <day>03</day>
          <month>12</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>03</day>
          <month>11</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>03</day>
          <month>12</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A s&#237;ndrome de Berardinelli-Seip (SBS) ou lipodistrofia generalizada cong&#234;nita acomete, frequentemente, o aparelho cardiovascular e tamb&#233;m promove anormalidades metab&#243;licas que envolvem os metabolismos glic&#237;dico e lip&#237;dico. OBJETIVO: Avaliar a preval&#234;ncia das anormalidades cardiovasculares e metab&#243;licas em portadores da SBS. M&#201;TODOS: Vinte e dois pacientes do Estado do Rio Grande do Norte (Brasil), com diagn&#243;stico da SBS, foram submetidos a avalia&#231;&#227;o cl&#237;nica, eletrocardiograma de repouso, ecodopplercardiograma, radiografia de t&#243;rax, eletrocardiografia din&#226;mica de 24 horas, teste ergom&#233;trico e an&#225;lise laboratorial. RESULTADOS: Os pacientes eram, predominantemente, adultos jovens, sendo a maioria do sexo feminino. A totalidade da amostra apresentou resist&#234;ncia &#224; insulina, acanthosis nigricans e HDL-colesterol diminu&#237;do. A presen&#231;a de esplenomegalia, hepatomegalia, diabetes mellitus tipo II e triglic&#233;rides elevados era constante. A s&#237;ndrome metab&#243;lica foi caracterizada na maioria dos pacientes, com predomin&#226;ncia no sexo feminino e com um alto grau de consanguinidade paterna. A hipertens&#227;o arterial sist&#234;mica e a pr&#233;-hipertens&#227;o foram encontradas em mais da metade dos pacientes (77,3%). O ecodopplercardiograma mostrou a presen&#231;a de hipertrofia conc&#234;ntrica do ventr&#237;culo esquerdo (50%), hipertrofia exc&#234;ntrica do ventr&#237;culo esquerdo (4,5%) e geometria normal do ventr&#237;culo esquerdo (45,5%). Elevada taxa de arritmia foi evidenciada no holter, tais como extrass&#237;stoles ventriculares, extrass&#237;stoles supraventriculares e taquicardia supraventricular sustentada. A incompet&#234;ncia cronotr&#243;pica (54,5%) foi observada no teste ergom&#233;trico. CONCLUS&#195;O: Anormalidades cardiovasculares e metab&#243;licas foram observadas em elevada preval&#234;ncia em indiv&#237;duos jovens e assintom&#225;ticos com SBS. Esses achados apontam para a necessidade de acompanhamento cardiol&#243;gico sistem&#225;tico e de medidas preventivas nesse grupo de risco.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Lipodistrofia Generalizada Cong&#234;nita</kwd>
        <kwd>Doen&#231;as Cardiovasculares</kwd>
        <kwd>Metabolismo</kwd>
        <kwd>Metabolismo dos Lip&#237;deos</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>22</day>
        <month>09</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> MIOCARDIOPATIAS</p>
    <p>
      <bold>Anormalidades cardiovasculares e metab&#243;licas em pacientes com a s&#237;ndrome de Berardinelli-Seip</bold>
    </p>
    <p>
      <bold>Antonio Guedes do R&#234;go<sup>I</sup>; Evandro Tinoco Mesquita<sup>II</sup>; Carlos Alberto de Faria<sup>I</sup>; Marcel &#193;lvares Guedes do R&#234;go<sup>III</sup>; Maria de F&#225;tima Paiva Baracho<sup>I</sup>; Maria Goretti do Nascimento Santos<sup>I</sup>; Eryvaldo S&#243;crates Tabosa do Egito<sup>I</sup>; Jos&#233; Brand&#227;o Neto<sup>I</sup></bold>
    </p>
    <p><sup>I</sup>Universidade Federal do Rio Grande do Norte (UFRN), Natal, RN </p>
    <p><sup>II</sup>Universidade Federal Fluminense (UFF), Niter&#243;i, RJ </p>
    <p><sup>III</sup>CLINICOR, Natal, RN, Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO: </bold> A s&#237;ndrome de Berardinelli-Seip (SBS) ou lipodistrofia generalizada cong&#234;nita acomete, frequentemente, o aparelho cardiovascular e tamb&#233;m promove anormalidades metab&#243;licas que envolvem os metabolismos glic&#237;dico e lip&#237;dico. </p>
    <p><bold>OBJETIVO: </bold> Avaliar a preval&#234;ncia das anormalidades cardiovasculares e metab&#243;licas em portadores da SBS. </p>
    <p><bold>M&#201;TODOS: </bold> Vinte e dois pacientes do Estado do Rio Grande do Norte (Brasil), com diagn&#243;stico da SBS, foram submetidos a avalia&#231;&#227;o cl&#237;nica, eletrocardiograma de repouso, ecodopplercardiograma, radiografia de t&#243;rax, eletrocardiografia din&#226;mica de 24 horas, teste ergom&#233;trico e an&#225;lise laboratorial. </p>
    <p><bold>RESULTADOS: </bold> Os pacientes eram, predominantemente, adultos jovens, sendo a maioria do sexo feminino. A totalidade da amostra apresentou resist&#234;ncia &#224; insulina, <italic>acanthosis nigricans</italic> e HDL-colesterol diminu&#237;do. A presen&#231;a de esplenomegalia, hepatomegalia, <italic>diabetes mellitus</italic> tipo II e triglic&#233;rides elevados era constante. A s&#237;ndrome metab&#243;lica foi caracterizada na maioria dos pacientes, com predomin&#226;ncia no sexo feminino e com um alto grau de consanguinidade paterna. A hipertens&#227;o arterial sist&#234;mica e a pr&#233;-hipertens&#227;o foram encontradas em mais da metade dos pacientes (77,3%). O ecodopplercardiograma mostrou a presen&#231;a de hipertrofia conc&#234;ntrica do ventr&#237;culo esquerdo (50%), hipertrofia exc&#234;ntrica do ventr&#237;culo esquerdo (4,5%) e geometria normal do ventr&#237;culo esquerdo (45,5%). Elevada taxa de arritmia foi evidenciada no <italic>holter</italic>, tais como extrass&#237;stoles ventriculares, extrass&#237;stoles supraventriculares e taquicardia supraventricular sustentada. A incompet&#234;ncia cronotr&#243;pica (54,5%) foi observada no teste ergom&#233;trico. </p>
    <p><bold>CONCLUS&#195;O:</bold> Anormalidades cardiovasculares e metab&#243;licas foram observadas em elevada preval&#234;ncia em indiv&#237;duos jovens e assintom&#225;ticos com SBS. Esses achados apontam para a necessidade de acompanhamento cardiol&#243;gico sistem&#225;tico e de medidas preventivas nesse grupo de risco.</p>
    <p><bold>Palavras chave: </bold> Lipodistrofia Generalizada Cong&#234;nita, Doen&#231;as Cardiovasculares/Gen&#233;tica, Metabolismo/Gen&#233;tica, Metabolismo dos Lip&#237;deos/Gen&#233;tica.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A s&#237;ndrome de Berardinelli-Seip (SBS) ou lipodistrofia generalizada cong&#234;nita foi descrita pela primeira vez no Brasil por Berardinelli e cols. em 1954, em duas crian&#231;as<sup>1</sup>. Seip e cols.<sup>2</sup>, em 1959, descreveram essa s&#237;ndrome em mais tr&#234;s pacientes<sup>2</sup>. A SBS possui um car&#225;ter gen&#233;tico com transmiss&#227;o autoss&#244;mica recessiva e frequente consanguinidade paterna, de causa indeterminada, devido &#224; muta&#231;&#227;o em AGPAT2 e Gng3lg<sup>3</sup>. Est&#227;o descritos dois loci, BSCL1 e BSCL2 na SBS, nos cromossomos 9q34 e 11q13, respectivamente<sup>3</sup>. Em estudo realizado em 21 dos pacientes do Rio Grande do Norte (Brasil), encontrou-se muta&#231;&#227;o no Gng3lg em 19 indiv&#237;duos e no AGPAT2<sup>4</sup> em dois.</p>
    <p>A SBS &#233; uma s&#237;ndrome rara com preval&#234;ncia de um caso para dez milh&#245;es de pessoas<sup>3</sup>. Os indiv&#237;duos acometidos com tal s&#237;ndrome s&#227;o caracterizados por apresentar <italic>diabetes mellitus</italic> tipo II, n&#227;o cet&#243;tico e insulino resistente, acompanhada de aus&#234;ncia quase completa de tecido adiposo subcut&#226;neo. O diagn&#243;stico pode ser estabelecido ao nascer ou durante a inf&#226;ncia e &#233; caracterizado por altera&#231;&#245;es cl&#237;nicas, metab&#243;licas e laboratoriais que incluem: diminui&#231;&#227;o ou aus&#234;ncia de tecido adiposo subcut&#226;neo, crescimento acelerado com padr&#227;o acromegal&#243;ide, desenvolvimento som&#225;tico e esquel&#233;tico acentuado. &#201; comum a presen&#231;a de hepatomegalia devido &#224; infiltra&#231;&#227;o de gordura que pode evoluir para cirrose, esplenomegalia, <italic>acanthosis nigricans</italic>, macroglossia, ginecomastia, hiperglicemia, hipertrigliceridemia, hiperinsulinemia, n&#237;veis diminu&#237;dos de colesterol de lipoprote&#237;na de alta densidade (HDL-c), podendo, ainda, haver eleva&#231;&#227;o do colesterol total (C-t) e do colesterol de lipoprote&#237;na de baixa densidade (LDL-c). Os n&#237;veis s&#233;ricos de leptina e adinopectina s&#227;o extremamente baixos<sup>3,5,6</sup>.</p>
    <p>H&#225; poucos estudos publicados na literatura sobre altera&#231;&#245;es card&#237;acas consequentes da SBS. Menos de vinte relatos reportaram altera&#231;&#245;es card&#237;acas, com casu&#237;stica inferior a dez pacientes<sup>7-14</sup>. Tais estudos apontaram como altera&#231;&#245;es cardiovasculares mais frequentes a hipertrofia card&#237;aca, cardiomegalia, cardiomiopatia hipertr&#243;fica, particularmente o padr&#227;o de hipertrofia septal assim&#233;trica, disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo e hipertens&#227;o arterial sist&#234;mica<sup>7-17</sup>. No Brasil, existe apenas o relato de um caso no qual foram descritas altera&#231;&#245;es card&#237;acas<sup>14</sup>.</p>
    <p>O objetivo deste trabalho foi determinar anormalidades cardiovasculares e metab&#243;licas em portadores da SBS, por meio de avalia&#231;&#227;o cl&#237;nica, exames bioqu&#237;micos, eletrocardiograma (ECG) de repouso, radiografia de t&#243;rax, teste ergom&#233;trico, ecodopplercardiograma e eletrocardiografia din&#226;mica de 24 horas (<italic>holter</italic>).</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>
      <bold>Indiv&#237;duos</bold>
    </p>
    <p>Foram estudados 22 pacientes portadores da SBS, provenientes do Estado do Rio Grande do Norte (Brasil) atendidos no Ambulat&#243;rio de Endocrinologia e Metabologia e de Cardiologia do Hospital Universit&#225;rio Onofre Lopes (HUOL) da Universidade Federal do Rio Grande do Norte (UFRN). Cada paciente ou seu representante legal assinou o Termo de Consentimento n&#186; 42/2003, que foi previamente aprovado pelo Comit&#234; de &#201;tica em Pesquisa da UFRN. Todos os exames foram realizados no mesmo dia, e nenhum paciente utilizava qualquer medicamento h&#225;, pelo menos, cinco dias.</p>
    <p>
      <bold>Par&#226;metros cl&#237;nicos</bold>
    </p>
    <p>Para cada participante, foi preenchido um protocolo que continha dados pessoais, anamnese e achados do exame f&#237;sico geral, endocrinol&#243;gico e cardiovascular. Todos os exames foram realizados por m&#233;dicos especialistas.</p>
    <p>
      <bold>Avalia&#231;&#227;o antropom&#233;trica</bold>
    </p>
    <p>As medidas de peso foram obtidas em tr&#234;s tomadas, com uso de balan&#231;a digital (Balmark, S&#227;o Paulo, SP, Brasil), com capacidade para 160 kg e sensibilidade de 100 g. A circunfer&#234;ncia abdominal (CA) foi medida sobre uma linha horizontal imagin&#225;ria que passava no ponto m&#233;dio entre a borda inferior da &#250;ltima costela e a crista il&#237;aca. A &#225;rea da superf&#237;cie corporal (ASC) foi calculada pela equa&#231;&#227;o de DuBois e DuBois<sup>18</sup>. As medidas de peso e altura foram utilizadas para o c&#225;lculo do &#237;ndice de massa corp&#243;rea (IMC). As crian&#231;as com IMC &gt; percentil 95 foram consideradas obesas, e aquelas com IMC entre os percentis 85 e 95, portadoras de sobrepeso<sup>19</sup>. Para os adultos, o IMC foi considerado normal entre 18,5-24,9 kg/m&#178;, sobrepeso entre 25,0-29,9 kg/m&#178; e obeso &gt; 30 kg/m&#178; <sup>20</sup>.</p>
    <p>
      <bold>Par&#226;metros bioqu&#237;micos</bold>
    </p>
    <p>Foram coletados 5 ml de sangue total, ap&#243;s jejum de 12 h. Foram dosados glicemia de jejum, C-t, HDL-c e triglic&#233;rides (TG). A lipoprote&#237;na de baixa densidade (LDL-c) n&#227;o foi calculada por se tornar progressivamente menos acurada com o aumento das concentra&#231;&#245;es s&#233;ricas de TG e n&#227;o ser utilizada para crit&#233;rios de s&#237;ndrome metab&#243;lica (SM)<sup>20</sup>. As dosagens foram realizadas em um analisador bioqu&#237;mico (Modelo Chem Well, Palm City, FL, USA), usando reagentes espec&#237;ficos (Labtest, Minas Gerais, Brasil).</p>
    <p>
      <bold>Crit&#233;rios e diretrizes</bold>
    </p>
    <p>Foram utilizados crit&#233;rios de normalidade definidos pela I Diretriz de Preven&#231;&#227;o da Aterosclerose na Inf&#226;ncia e na Adolesc&#234;ncia<sup>19</sup>, pela IV Diretriz de Preven&#231;&#227;o da Aterosclerose da Sociedade Brasileira de Cardiologia<sup>20</sup> e pelo Consenso Brasileiro sobre Diabetes<sup>21</sup>. Os registros de informa&#231;&#245;es, em rela&#231;&#227;o &#224; resist&#234;ncia &#224; insulina de cada indiv&#237;duo, foram obtidos nos prontu&#225;rios do HUOL.</p>
    <p>Para avaliar os crit&#233;rios de SM em crian&#231;as e adolescentes, foram adotados os crit&#233;rios da NCEP/ATP III<sup>22</sup> modificado para a idade, sendo necess&#225;ria a presen&#231;a de, pelo menos, tr&#234;s a cinco par&#226;metros: n&#237;veis de TG <underline>&gt;</underline> 110 mg/dl; HDL-c <underline>&lt;</underline> 40 mg/dl; circunfer&#234;ncia abdominal <underline>&gt;</underline> percentil 90, segundo sexo e idade; glicemia <underline>&gt;</underline> 110 mg/dL e press&#227;o arterial sist&#243;lica ou diast&#243;lica (PAS ou PAD) <underline>&gt;</underline> percentil 90 segundo sexo, idade e estatura. Por outro lado, a NCEP/ATP III<sup>23</sup> preconiza que, para os adultos, a SM representa a combina&#231;&#227;o de, pelo menos, tr&#234;s dos seguintes componentes: obesidade abdominal por meio de circunfer&#234;ncia abdominal (homens &gt; 102 cm e mulheres &gt; 88 cm); TG <underline>&gt;</underline> 150 mg/dl: HDL-c para homens &lt; 40 mg/dl e mulheres &lt; 50 mg/dl; press&#227;o arterial <underline>&gt;</underline> 130 mmHg ou <underline>&gt;</underline> 85 mmHg; e glicemia de jejum <underline>&gt;</underline> 110 mg/dL. A presen&#231;a de <italic>diabetes mellitus</italic> tipo II n&#227;o exclui o diagn&#243;stico de SM. Pela sua simplicidade e praticidade, essa &#233; a defini&#231;&#227;o recomendada pela I Diretriz Brasileira de Diagn&#243;stico e Tratamento da S&#237;ndrome Metab&#243;lica<sup>24</sup>.</p>
    <p>
      <bold>Par&#226;metros hemodin&#226;micos</bold>
    </p>
    <p>As press&#245;es arteriais (PA) foram aferidas pelo m&#233;todo indireto, por meio de esfigmoman&#244;metro (Welch Allyn, Skaneateles Falls, NY, USA) graduado e calibrado de zero a 300 mmHg. Foram verificadas tr&#234;s medidas ap&#243;s cinco minutos de repouso com o paciente na posi&#231;&#227;o sentada. Os procedimentos das medidas e a classifica&#231;&#227;o da press&#227;o arterial foram realizados de acordo com o <italic>The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents</italic> e o <italic>Seventh Report</italic> do <italic>Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</italic><sup>25,26</sup>. Os valores da PA n&#227;o foram arredondados para d&#237;gitos terminados em cinco ou zero.</p>
    <p>
      <bold>Eletrocardiograma</bold>
    </p>
    <p>O eletrocardiograma de repouso (ECG), realizado ap&#243;s dez minutos de repouso, foi registrado em um aparelho de eletrocardiografia (Cardioline Delta Plus, Cavareno, Trento, It&#225;lia) com 12 deriva&#231;&#245;es. O registro gr&#225;fico foi padronizado na velocidade de 25 mm/s, e o aparelho foi calibrado com amplitude de 1 mV, correspondendo a 10 mm no eixo vertical<sup>27</sup>. A avalia&#231;&#227;o final foi realizada por dois cardiologistas; havendo discord&#226;ncia, um terceiro profissional determinou o resultado final do exame.</p>
    <p>
      <bold>Radiografia tor&#225;cica</bold>
    </p>
    <p>O raio X de t&#243;rax foi realizado em um aparelho (Emic, Modelo MKTE 500, S&#227;o Paulo, SP, Brasil) com sistema de processamento digital marca Agfa Cr 75.0 (Mortsel-Belgium) em inspira&#231;&#227;o m&#225;xima. Para as crian&#231;as que n&#227;o puderam ficar em inspira&#231;&#227;o m&#225;xima, o exame foi realizado com uma dist&#226;ncia de 1 m, geralmente na proje&#231;&#227;o anteroposterior. Nos adultos, a dist&#226;ncia foi de 1,75 a 2 m em proje&#231;&#227;o anteroposterior e perfil esquerdo. Usando tal t&#233;cnica, foram avaliadas a &#225;rea card&#237;aca, mediante o &#237;ndice cardiotor&#225;cico e a avalia&#231;&#227;o pleuropulmonares, e as c&#250;pulas diafragm&#225;ticas<sup>28</sup>.</p>
    <p>
      <bold>Ecodopplercardiograma</bold>
    </p>
    <p>Esse exame realizado foi uni e bidimensional com <italic>doppler</italic> pulsado e cont&#237;nuo com mapeamento de fluxo a cores (Hewlett Packard, Modelo 2410 A-Ultrasound System, Andover-MA, USA). Foram realizadas cinco medidas para cada vari&#225;vel estudada, e o valor m&#233;dio final foi o considerado para a an&#225;lise. O aparelho continha transdutores de 2.5 e 5.0 mHz, que permitiram a avalia&#231;&#227;o no modo-M e no bidimensional com <italic>doppler</italic> pulsado e cont&#237;nuo. As imagens foram obtidas seguindo-se as recomenda&#231;&#245;es da <italic>American Society of Echocardiography</italic> (ASE)<sup>29,30</sup> a partir de cortes ecocardiogr&#225;ficos convencionais.</p>
    <p>Para o c&#225;lculo da massa ventricular esquerda, foi adotada a f&#243;rmula recomendada pela ASE, corrigida pela Conven&#231;&#227;o de Penn<sup>31</sup>. O &#237;ndice de massa ventricular esquerda (IMVE) foi calculado corrigindo-se o valor da massa (g) pela ASC (m&#178;). Foi considerado normal IMVE menor ou igual a 95 g/m&#178; e 115g/m&#178; para mulheres e homens, respectivamente<sup>32</sup>. O c&#225;lculo da espessura relativa da parede (ERP) foi obtido pela f&#243;rmula abaixo:</p>
    <p>ERP = (2 x EPPd) / DdV</p>
    <p>EPPd e DdV s&#227;o a espessura diast&#243;lica da parede posterior e o di&#226;metro diast&#243;lico final do ventr&#237;culo esquerdo, respectivamente.</p>
    <p>Os pacientes foram classificados em quatro grupos de geometria card&#237;aca<sup>32</sup>:</p>
    <p>a) Geometria normal = IMVE normal e ERP <underline>&lt;</underline> 0.42.</p>
    <p>b) Remodela&#231;&#227;o conc&#234;ntrica = IMVE normal e ERP &gt; 0,42.</p>
    <p>c) Hipertrofia conc&#234;ntrica = IMVE aumentada e ERP&gt; 0,42.</p>
    <p>d) Hipertrofia exc&#234;ntrica = IMVE aumentada e ERP <underline>&lt;</underline> 0,42.</p>
    <p>A fra&#231;&#227;o de eje&#231;&#227;o (FE) foi calculada pelo m&#233;todo de Simpson a partir de um corte apical de quatro c&#226;maras<sup>32</sup>. Foram considerados normais valores <underline>&gt;</underline> 55%.</p>
    <p>As avalia&#231;&#245;es dos fluxos intracard&#237;acos seguiram as orienta&#231;&#245;es do Consenso Canadense e serviram para avaliar a fun&#231;&#227;o diast&#243;lica do ventr&#237;culo esquerdo<sup>33</sup>. Foram obtidas as seguintes vari&#225;veis:</p>
    <p>a) Velocidade m&#225;xima de enchimento ventricular r&#225;pido do fluxo transmital (pico da onda E em m/s).</p>
    <p>b) Velocidade m&#225;xima de enchimento tardio do fluxo transmital (pico da onda A em m/s).</p>
    <p>c) Rela&#231;&#227;o onda E/onda A.</p>
    <p>d) Tempo de desacelera&#231;&#227;o da onda E (TDE) do fluxo transmital em m/s correspondente ao intervalo de tempo entre o pico da onda E e sua extrapola&#231;&#227;o para a linha de base.</p>
    <p>e) Tempo de relaxamento isovolum&#233;trico do ventr&#237;culo esquerdo (TRIV) em m/s correspondente ao intervalo tempo entre o final do fluxo sist&#243;lico e o in&#237;cio do fluxo transmitral.</p>
    <p>As tr&#234;s primeiras vari&#225;veis foram obtidas antes e durante a fase de press&#227;o da manobra de Valsalva.</p>
    <p>
      <bold>Eletrocardiografia din&#226;mica de 24 horas (<italic>holter</italic>)</bold>
    </p>
    <p>Os pacientes foram monitorados durante 24 horas, utilizando um gravador (Cardioflash Digital Cardios, S&#227;o Paulo, SP, Brasil). O preparo, a realiza&#231;&#227;o do exame, a an&#225;lise e o laudo seguiram as orienta&#231;&#245;es do <italic>ACC/AHA Guidelines for Ambulatory Eletrocardiography</italic><sup>34</sup>.</p>
    <p>
      <bold>Teste ergom&#233;trico</bold>
    </p>
    <p>Foi realizado em uma esteira (IMBRAMED, Modelo Soft Move I, Porto Alegre, RS, Brasil). Os pacientes foram preparados para monitoriza&#231;&#227;o de ECG cont&#237;nuo, utilizando as deriva&#231;&#245;es modificadas de Mason e cols.<sup>35</sup>. Iniciou-se o exame utilizando-se o protocolo de Bruce<sup>36</sup>. Objetivando avaliar respostas cl&#237;nicas, eletrocardiogr&#225;ficas e hemodin&#226;micas, o exame seguiu as orienta&#231;&#245;es para resultados fi&#233;is, reprodut&#237;veis e mensur&#225;veis mencionadas nas II Diretrizes da Sociedade Brasileira de Cardiologia Sobre Teste Ergometrico<sup>37</sup>.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>A compara&#231;&#227;o entre os dois subgrupos foi analisada pelo teste de Mann-Whitney para dados num&#233;ricos e pelo teste exato de Fisher para dados categ&#243;ricos (qualitativos). Os dados num&#233;ricos foram sumarizados por meio de m&#233;dia e desvio padr&#227;o, e os dados qualitativos foram expressos por meio de frequ&#234;ncia (n) e percentual (%). Foi utilizado teste n&#227;o param&#233;trico de Mann-Whitney, pois as vari&#225;veis n&#227;o apresentaram distribui&#231;&#227;o normal (distribui&#231;&#227;o Gaussiana) devido &#224; falta de simetria da distribui&#231;&#227;o e, principalmente, devido ao tamanho da amostra reduzida nos subgrupos estudados. O crit&#233;rio de determina&#231;&#227;o de signific&#226;ncia adotado foi o n&#237;vel de 5%. A an&#225;lise estat&#237;stica foi processada pelo <italic>software</italic> SAS 6.04 (SAS Institute, Inc., Cary, North Carolina, USA).</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>
      <bold>Indiv&#237;duos</bold>
    </p>
    <p>As caracter&#237;sticas cl&#237;nicas dos 22 pacientes estudados est&#227;o reunidas na <xref ref-type="fig" rid="f1">figura 1</xref> e na <xref ref-type="table" rid="t01">tabela 1</xref>.</p>
    <p content-type="asset">
      <table-wrap id="t01">
        <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt01.jpg"/></table-wrap>
    </p>
    <fig id="f1">
      <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gf01.jpg"/></fig>
    <p>
      <bold>Par&#226;metros cl&#237;nicos</bold>
    </p>
    <p>Na <xref ref-type="table" rid="t01">tabela 1</xref>, tamb&#233;m est&#227;o descritos os par&#226;metros cl&#237;nicos. A hist&#243;ria familiar da SBS foi identificada em 86,4% dos pacientes, com predomin&#226;ncia do sexo feminino (92,9%) por causa do maior n&#250;mero. O <italic>diabetes mellitus</italic> tipo II ocorreu em 68,2% dos pacientes, sendo 62,5% no sexo masculino. O diagn&#243;stico de resist&#234;ncia &#224; insulina e <italic>acanthosis nigricans</italic> foi demonstrado em todos os pacientes. A SM ocorreu em 81,8% dos casos com preval&#234;ncia semelhante entre os sexos. A hepatomegalia ocorreu em 90,9% dos pacientes sem diferen&#231;a entre os sexos, e a esplenomegalia, em 45,5%, predominantemente no sexo feminino.</p>
    <p>
      <bold>Avalia&#231;&#227;o antropom&#233;trica</bold>
    </p>
    <p>As caracter&#237;sticas antropom&#233;tricas dos 22 pacientes estudados est&#227;o reunidas na <xref ref-type="table" rid="t01">tabela 1</xref>. A m&#233;dia de idade foi de 22.4 &#177; 9.7 anos, sem diferen&#231;a estat&#237;stica entre os sexos. A m&#233;dia do peso foi de 56.6 &#177; 15.1 kg, sendo mais elevado no sexo masculino (p = 0.003). O IMC apresentou a m&#233;dia de 21.6 &#177; 3.3, sendo mais expressivo no sexo masculino (p = 0.001). A m&#233;dia da ASC foi de 1.58 &#177; 0.27, mais elevado no sexo masculino (p = 0.004). A CA apresentou a m&#233;dia de 82 &#177; 9.2, significativamente mais elevada no sexo masculino (p = 0.011).</p>
    <p>
      <bold>Par&#226;metros bioqu&#237;micos</bold>
    </p>
    <p>A glicemia de jejum manteve-se em m&#233;dia elevada, 177,8 &#177; 84,4, sem diferen&#231;a significativa entre os sexos. A m&#233;dia do C-t foi de 175,4 &#177; 38,1, sem diferen&#231;a estat&#237;stica entre os sexos. A m&#233;dia do HDL-c foi 27,4 &#177; 7,7, mais elevado no sexo feminino (p = 0.033). Os TG permaneceram elevados, 331,7 &#177; 286,4, embora sem diferen&#231;a entre ambos os sexos (<xref ref-type="table" rid="t01">tabela 1</xref>).</p>
    <p>
      <bold>Press&#227;o arterial</bold>
    </p>
    <p>A frequ&#234;ncia card&#237;aca basal teve a m&#233;dia de 91,6 &#177; 8,3, mais elevada no sexo feminino (p = 036). A hipertens&#227;o arterial sist&#234;mica (HAS) ocorreu em 50%, e a pr&#233;-hipertens&#227;o, em 27,3% dos pacientes com SBS (<xref ref-type="table" rid="t01">tabela 1</xref>). As m&#233;dias das PAS e PAD eram aumentadas em ambos os sexos, embora sem diferen&#231;a estat&#237;stica.</p>
    <p>
      <bold>Eletrocardiograma</bold>
    </p>
    <p>Todos os pacientes com a SBS mostraram ritmo sinusal, 18,2% apresentaram hipertrofia ventricular esquerda (HVE), e 3,6%, altera&#231;&#227;o da repolariza&#231;&#227;o ventricular. Outras altera&#231;&#245;es foram pequenas (dados n&#227;o mostrados).</p>
    <p>
      <bold>Radiografia tor&#225;cica</bold>
    </p>
    <p>Dos 22 pacientes com a SBS, 95,5% apresentaram radiografia do t&#243;rax normal. Somente uma mulher apresentou aumento da &#225;rea card&#237;aca e invers&#227;o do fluxo pulmonar para os &#225;pices (dados n&#227;o mostrados).</p>
    <p>
      <bold>Ecodopplercardiograma</bold>
    </p>
    <p>Na <xref ref-type="table" rid="t02">tabela 2</xref>, os achados do ecodopplercardiograma mostraram-se normais em 40,9% dos pacientes, sem signific&#226;ncia estat&#237;stica entre os sexos. A regurgita&#231;&#227;o mitral leve apareceu em 27,3% dos pacientes com a SBS, com predomin&#226;ncia no sexo feminino. Foram diagnosticadas a calcifica&#231;&#227;o da valva a&#243;rtica em 9,1% dos pacientes e a presen&#231;a de 4,5% com regurgita&#231;&#227;o a&#243;rtica leve apenas nos pacientes do sexo feminino. A hipertrofia conc&#234;ntrica do ventr&#237;culo esquerdo (HCVE) apareceu na ordem de 50% dos pacientes de ambos os sexos, e a hipertrofia exc&#234;ntrica do ventr&#237;culo esquerdo, em 4,5%, predominantemente no sexo feminino. Geometria normal do ventr&#237;culo esquerdo esteve presente em 45,5% dos casos estudados, praticamente igual entre os sexos. Os padr&#245;es da fun&#231;&#227;o diast&#243;lica avaliados pelo fluxo transmitral estavam dentro da normalidade, antes da e durante a fase de press&#227;o da manobra de Valsalva (<xref ref-type="table" rid="t02">tabela 2</xref>). No tocante &#224; avalia&#231;&#227;o da fun&#231;&#227;o sist&#243;lica, vale ressaltar que a fra&#231;&#227;o de eje&#231;&#227;o (Simpson) do VE teve valor m&#233;dio de 67.3%, sem diferen&#231;a entre os sexos.</p>
    <p content-type="asset">
      <table-wrap id="t02">
        <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt02.jpg"/></table-wrap>
    </p>
    <p>A <xref ref-type="table" rid="t03">tabela 3</xref> relaciona a frequ&#234;ncia e a percentagem de HVE no eletrocardiograma e os par&#226;metros cl&#237;nicos com o ecodopplercardiograma (normal ou anormal). A HVE no ECG (30,8%), <italic>diabetes mellitus</italic> (76,9%), hepatomegalia (100%), esplenomegalia (61,5%) e HAS mais pr&#233;-hipertens&#227;o (92,3%) estavam mais presentes no ECO anormal.</p>
    <p content-type="asset">
      <table-wrap id="t03">
        <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt03.jpg"/></table-wrap>
    </p>
    <p>A <xref ref-type="table" rid="t04">tabela 4</xref> relaciona a frequ&#234;ncia e a percentagem de v&#225;rios par&#226;metros cl&#237;nicos e HVE no eletrocardiograma com a hipertrofia conc&#234;ntrica do ventr&#237;culo esquerdo no ecocardiograma. Entre os par&#226;metros eletrocardiogr&#225;ficos, 36,4% da HVE foram detectados apenas na presen&#231;a de HCVE. Os par&#226;metros cl&#237;nicos mais frequentes, tais como <italic>diabetes mellitus</italic> (72,7%), hepatomegalia (100%), esplenomegalia (63,6%) e HAS mais pr&#233;-hipertens&#227;o (90,9%), foram mais observados na presen&#231;a da HCVE do que na sua aus&#234;ncia.</p>
    <p content-type="asset">
      <table-wrap id="t04">
        <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt04.jpg"/></table-wrap>
    </p>
    <p>
      <bold>Holter eletrocardiograma</bold>
    </p>
    <p>A <xref ref-type="table" rid="t05">tabela 5</xref> mostra a associa&#231;&#227;o entre as arritmias verificadas no <italic>holter</italic> e a incompet&#234;ncia cronotr&#243;pica verificada no teste ergom&#233;trico (TE) em rela&#231;&#227;o &#224; HCVE observada no ecocardiograma em 22 pacientes com SBS. Pacientes com <italic>holter</italic> normal foram observados com a HCVE presente (18,2%) e ausente (36,4%), sem signific&#226;ncia entres eles. Extrass&#237;stoles ventriculares foram igualmente detectadas em 54,6% dos pacientes com HCVE presente e ausente. Pacientes com extrass&#237;stoles supraventriculares apresentaram a percentagem de 81,8% associada &#224; presen&#231;a de HCVE e 54,6% &#224; HCVE ausente. Taquicardia supraventricular sustentada foi detectada em 27,3% dos pacientes com HCVE presente e 9,1% com HCVE ausente.</p>
    <p content-type="asset">
      <table-wrap id="t05">
        <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt05.jpg"/></table-wrap>
    </p>
    <p>
      <bold>Teste ergom&#233;trico</bold>
    </p>
    <p>A incompet&#234;ncia cronotr&#243;pica foi observada no TE em 45,5% dos pacientes com HCVE presente e em 63,6% com HCVE ausente, sem diferen&#231;a estat&#237;stica (<xref ref-type="table" rid="t05">tabela 5</xref>).</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>A SBS foi descrita em menos de 300 pacientes at&#233; o presente momento. A literatura atual sugere que apenas um em cada quatro casos &#233; relatado, o que permite uma estimativa da doen&#231;a em torno de um para cada 10.000.000 habitantes<sup>3</sup>. O Estado do Rio Grande do Norte (Brasil) tem uma popula&#231;&#227;o estimada de 3.000.000 habitantes. Portanto, nosso grupo constitui uma amostra bastante significativa e a maior casu&#237;stica da literatura mundial.</p>
    <p>A ocorr&#234;ncia de anormalidades cardiovasculares e metab&#243;licas em portadores da SBS, atualmente, &#233; pouco discutida. Neste estudo, a preval&#234;ncia da consanguinidade paterna, <italic>diabete mellitus</italic> tipo II, resist&#234;ncia &#224; insulina, <italic>acanthosis nigricans</italic>, hepatomegalia, esplenomegalia, HDL-c diminu&#237;dos e TG aumentados foram semelhantes aos encontrados na literatura (<xref ref-type="table" rid="t01">tabela1</xref>)<sup>3,6,10,11,14,15,17</sup>.</p>
    <p>Um dado relevante deste estudo foi que, pela primeira vez, se identificou a SM em pacientes com SBS. Ela foi encontrada na grande maioria dos pacientes, predominando em ambos os sexos. Ela foi encontrada em 18 pacientes (81,8%), sendo 11 (78,6%) do sexo feminino. Das sete crian&#231;as e adolescentes (31,81%) deste estudo, seis tinham crit&#233;rios para a SM, sendo cinco (71,42%) do sexo feminino e um (14,28%) do sexo masculino. Os crit&#233;rios mais prevalentes foram baixo HDL-c (81,81%), hiperglicemia (77,27%), hipertrigliceridemia (63,63%) e hipertens&#227;o arterial sist&#234;mica (50%). Em rela&#231;&#227;o &#224; circunfer&#234;ncia abdominal, nenhum paciente apresentou aumento dessa vari&#225;vel. Os pacientes do sexo masculino apresentaram a circunfer&#234;ncia abdominal mais elevada do que os do sexo feminino, o que implica maiores cuidados preventivos relacionados &#224;s cardiopatias (<xref ref-type="table" rid="t01">tabela 1</xref>). Esses achados foram bastante significativos pela alta incid&#234;ncia encontrada na SBS e por serem representativos do aumento da mortalidade geral e das complica&#231;&#245;es cardiovasculares<sup>24</sup>.</p>
    <p>Todos os pacientes n&#227;o tiveram bom controle da glicemia de jejum, al&#233;m de apresentarem HDL-c diminu&#237;dos e TG elevados. Esses resultados foram semelhantes aos encontrados na literatura (<xref ref-type="table" rid="t01">tabela 1</xref>)<sup>3,6,10,11,14,15,17</sup>. A associa&#231;&#227;o de HDL-c baixo e eleva&#231;&#227;o de TG aumentam enormemente os fatores de risco para as doen&#231;as cardiovasculares<sup>24</sup>.</p>
    <p>A hipertens&#227;o arterial sist&#234;mica foi observada em 50% dos pacientes. Esses resultados est&#227;o em completa concord&#226;ncia com outros autores que os encontraram em 46,5% dos 13 relatos de casos estudados<sup>2,8,16</sup>. A pr&#233;-hipertens&#227;o, n&#227;o descrita anteriormente, foi identificada em 27,3% dos pacientes (<xref ref-type="table" rid="t01">tabela 1</xref>). Essa classifica&#231;&#227;o da pr&#233;-hipertens&#227;o &#233; particularmente importante para o tratamento dos pacientes com SM e <italic>diabetes mellitus</italic><sup>24,26</sup>.</p>
    <p>Outro dado relevante encontrado nesse estudo diz respeito aos resultados obtidos com o eletrocardiograma e a radiografia de t&#243;rax. Ambos os par&#226;metros n&#227;o foram &#250;teis para identificar a presen&#231;a de anormalidades card&#237;acas na SBS, em particular a presen&#231;a de HVE. Diferente de outros estudos que encontraram cardiomegalia como um achado frequente na radiografia de t&#243;rax<sup>7,8,11,13,16</sup>, foi observado apenas um caso no presente estudo (dado n&#227;o mostrado). Portanto, para identificar o acometimento cardiovascular, foi indispens&#225;vel o estudo ecodopplercardiogr&#225;fico.</p>
    <p>Em rela&#231;&#227;o &#224;s anormalidades ecocardiogr&#225;ficas deste estudo, observou-se elevada preval&#234;ncia de acometimento card&#237;aco por meio da presen&#231;a de hipertrofia conc&#234;ntrica do ventr&#237;culo esquerdo (50%), em ambos os sexos, semelhante aos achados de outros autores<sup>7,8,14,15,17</sup>. Por outro lado, n&#227;o foi encontrado caso de cardiomiopatia hipertr&#243;fica, embora a mesma seja bastante citada na literatura como achado frequente<sup>6-8,11-13,15,38</sup>. Observaram-se 4,5% dos pacientes com hipertrofia exc&#234;ntrica do ventr&#237;culo esquerdo. Regurgita&#231;&#227;o mitral leve foi observada em seis pacientes com SBS. Apenas um paciente apresentava hipocinesia global do ventr&#237;culo esquerdo e disfun&#231;&#227;o sist&#243;lica (<xref ref-type="table" rid="t02">tabela 2</xref>).</p>
    <p>
      <bold>Resist&#234;ncia &#224; insulina e cardiopatias</bold>
    </p>
    <p>A possibilidade de a resist&#234;ncia &#224; insulina ocasionar hipertrofia do mi&#243;cito &#233; o prov&#225;vel eixo histopatol&#243;gico, tendo em vista a presen&#231;a de aumento dos di&#226;metros das fibras e a aus&#234;ncia de crit&#233;rios de cardiomiopatia hipertr&#243;fica. Na verdade, essa cardiomiopatia ocorre em pacientes com s&#237;ndrome de resist&#234;ncia &#224; insulina por uma a&#231;&#227;o direta da insulina nos receptores do fator de crescimento semelhante &#224; insulina (IGF-1)<sup>10</sup>. A alta frequ&#234;ncia de tal patologia associada &#224; hipertrofia conc&#234;ntrica em tais pacientes tamb&#233;m &#233; relatada por Klar e cols.<sup>12</sup> em 1993. Em achados de autopsia, as fibras estavam arranjadas, sem dep&#243;sito de glicog&#234;nio e infiltra&#231;&#227;o gordurosa<sup>8,13</sup>. A cardiomiopatia hipertr&#243;fica associada com <italic>diabetes melittus</italic> &#233; associada, com frequ&#234;ncia, &#224; dilata&#231;&#227;o ventricular e &#224;s altera&#231;&#245;es das art&#233;rias coron&#225;rias<sup>13</sup>. Neste estudo, foi encontrado apenas um paciente com aumento dos di&#226;metros internos do VE (hipertrofia exc&#234;ntrica) (<xref ref-type="table" rid="t02">tabela 2</xref>). A diferencia&#231;&#227;o histol&#243;gica com a cardiomiopatia hipertr&#243;fica cl&#225;ssica &#233; feita pela aus&#234;ncia de desarranjo das fibras na hipertrofia associada lipodistrofia<sup>12,14</sup>.</p>
    <p>Divergindo de outros estudos que identificaram elevada taxa de disfun&#231;&#227;o diast&#243;lica pela avalia&#231;&#227;o do fluxo transmitral<sup>7,8,13,14</sup>, n&#227;o foi encontrada a disfun&#231;&#227;o diast&#243;lica em nossos pacientes, mesmo ap&#243;s o emprego da manobra de Valsalva. Outro achado discordante da literatura<sup>8,11,15,38,39</sup> consistiu na presen&#231;a de disfun&#231;&#227;o sist&#243;lica. Apenas um paciente neste estudo apresentou disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo. Uma das limita&#231;&#245;es do nosso trabalho foi n&#227;o utilizar o <italic>doppler</italic> tecidual ainda n&#227;o dispon&#237;vel em nosso servi&#231;o.</p>
    <p>O <italic>holter</italic> identificou elevada taxa de arritmia card&#237;aca em portadores da SBS. Apesar da baixa m&#233;dia de idade (22,4% &#177; 9.7) desses pacientes, 54,6% apresentaram extrass&#237;stoles ventriculares com HCVE presente, e outros 54,6%, com HCVE ausente (<xref ref-type="table" rid="t05">tabela 5</xref>). Em rela&#231;&#227;o &#224; literatura, existe apenas um relato de uma paciente de cinco anos, que foi monitorizada por 24 horas e com <italic>holter</italic> normal<sup>38</sup>.</p>
    <p>Em rela&#231;&#227;o ao teste ergom&#233;trico, observou-se incompet&#234;ncia cronotr&#243;pica em 45,5% dos pacientes com HCVE presente e em 63,6% nos pacientes com HCVE ausente (<xref ref-type="table" rid="t05">tabela 5</xref>). Esse teste foi normal para isquemia mioc&#225;rdica nos pacientes que atingiram a FC desejada e nos que apresentaram incompet&#234;ncia cronotr&#243;pica. N&#227;o houve rela&#231;&#227;o entre incompet&#234;ncia cronotr&#243;pica e HCVE presente ou ausente. A presen&#231;a de incompet&#234;ncia cronotr&#243;pica &#233; um preditor de aumento da mortalidade card&#237;aca e doen&#231;a coronariana incipiente, por n&#227;o atingir a FC desejada<sup>40</sup>. A grande relev&#226;ncia desse achado reside no fato de n&#227;o haver trabalho na literatura que correlacione teste ergom&#233;trico e incompet&#234;ncia cronotr&#243;pica nos portadores dessa s&#237;ndrome.</p>
    <p>Finalmente, a morte s&#250;bita &#233; relatada nos poucos casos com altera&#231;&#245;es card&#237;acas. &#201; descrita a rela&#231;&#227;o de altera&#231;&#245;es card&#237;acas e dislipidemia como causa de morte s&#250;bita na SBS<sup>8,12</sup>. As altera&#231;&#245;es card&#237;acas aumentam com a idade<sup>7,8</sup>, o que diverge neste estudo.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Como conclus&#245;es preliminares, os resultados obtidos revelaram anormalidades cardiovasculares e metab&#243;licas com elevada preval&#234;ncia em pacientes jovens, assintom&#225;ticos e portadores da SBS. Esses achados apontam para a necessidade de acompanhamento cardiol&#243;gico e de medidas preventivas nesse grupo de risco.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo foi parcialmente financiado pelo MCT/FINEP/SINTEC, 01/2003</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de Doutorado de Ant&#244;nio Guedes do R&#234;go pela Universidade Federal do Rio Grande do Norte (UFRN).</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Jos&#233; Brand&#227;o Neto </p>
        <p> Universidade Federal do Rio Grande do Norte </p>
        <p> P&#243;s-gradua&#231;&#227;o em Ci&#234;ncias da Sa&#250;de </p>
        <p> Rua Paulo Lyra, 2183 / 1301 - Candel&#225;ria </p>
        <p> 59010-180, Natal, RN, Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="jbn@ppgcsa.com.br">jbn@ppgcsa.com.br</email> e </p>
        <p>
          <email xlink:href="aguedesrego@cardiol.br">aguedesrego@cardiol.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 03/11/08; revisado recebido em 03/12/08, aceito em 03/12/08</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Berardinelli    W. An undiagnosed endocrinometabolic syndrome: report of 2 cases. J Clin Endocrinol    Metab. 1954; 14 (2): 193-204.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>An undiagnosed endocrinometabolic syndrome: report of 2 cases</article-title>
          <source>J Clin Endocrinol Metab</source>
          <date>
            <year>1954</year>
          </date>
          <fpage>193</fpage>
          <lpage>204</lpage>
          <issue>2</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Berardinelli</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Seip M. Lipodystrophy    and gigantism with associated endocrine manifestations: a new diencephalic syndrome?    Acta Paediatr Scand. 1959; 48: 555-74.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Lipodystrophy and gigantism with associated endocrine manifestations: a new diencephalic syndrome?</article-title>
          <source>Acta Paediatr Scand</source>
          <date>
            <year>1959</year>
          </date>
          <fpage>555</fpage>
          <lpage>74</lpage>
          <volume>48</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Seip</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Garg A. Medical    progress: acquired and inherited lipodystrophies. N Engl J Med. 2004; 350 (12):    1220-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Medical progress: acquired and inherited lipodystrophies</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1220</fpage>
          <lpage>34</lpage>
          <issue>12</issue>
          <volume>350</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Fu M, Kazlauskaite    R, Baracho MF, Santos MGN, Brand&#227;o Neto J, Villares S, et al. Mutations    in Gng3lg and AGPAT2 in Berardinelli-Seip congenital lipodystrophy and Brunzell    syndrome: phenotype variability suggests important modifier effects. J Clin    Endocrinol Metab. 2004; 89 (6): 2916-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mutations in Gng3lg and AGPAT2 in Berardinelli-Seip congenital lipodystrophy and Brunzell syndrome: phenotype variability suggests important modifier effects</article-title>
          <source>J Clin Endocrinol Metab</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>2916</fpage>
          <lpage>22</lpage>
          <issue>6</issue>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kazlauskaite</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Baracho</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>MGN</given-names>
            </name>
            <name>
              <surname>Brand&#227;o Neto</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Villares</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Haque WA, Shimomura    I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with    lipodystrophies. J Clin Endocrinol Metab. 2002; 87 (5): 2395.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Serum adiponectin and leptin levels in patients with lipodystrophies</article-title>
          <source>J Clin Endocrinol Metab</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>2395</fpage>
          <issue>5</issue>
          <volume>87</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Haque</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Shimomura</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Matsuzawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Garg A. Lipodystrophies.    Am J Med. 2000; 108 (2): 143-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Lipodystrophies</article-title>
          <source>Am J Med</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>143</fpage>
          <lpage>52</lpage>
          <issue>2</issue>
          <volume>108</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Bjornstad PG,    Semb BKH, Trygstad O, Seip M. Echocardiographic assessment of cardiac-function    and morphology in patients with generalized lipodystrophy. Eur J Pediatr. 1985;    144 (4): 355-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Echocardiographic assessment of cardiac-function and morphology in patients with generalized lipodystrophy</article-title>
          <source>Eur J Pediatr</source>
          <date>
            <year>1985</year>
          </date>
          <fpage>355</fpage>
          <lpage>9</lpage>
          <issue>4</issue>
          <volume>144</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bjornstad</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Semb</surname>
              <given-names>BKH</given-names>
            </name>
            <name>
              <surname>Trygstad</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Seip</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Bjornstad PG,    Foerster A, Ihlen H. Cardiac findings in generalized lipodystrophy. Acta Paediatr    Suppl. 1996; 413: 39-43.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac findings in generalized lipodystrophy</article-title>
          <source>Acta Paediatr Suppl</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>39</fpage>
          <lpage>43</lpage>
          <volume>413</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bjornstad</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Foerster</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ihlen</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Chandalia M,    Garg A, Vuitch F, Nizzi F. Postmortem findings in congenital generalized lipodystrophy.    J Clin Endocrinol Metab. 1995, 80 (10): 3077-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Postmortem findings in congenital generalized lipodystrophy</article-title>
          <source>J Clin Endocrinol Metab</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>3077</fpage>
          <lpage>81</lpage>
          <issue>10</issue>
          <volume>80</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chandalia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vuitch</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Nizzi</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Geffner ME,    Santulli TV, Kaplan SA. Hypertrophic cardiomyopathy in total lipodystrophy:    insulin action in the face of insulin resistance. J. Pediatr. 1987; 110 (1):    161.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hypertrophic cardiomyopathy in total lipodystrophy: insulin action in the face of insulin resistance</article-title>
          <source>J. Pediatr</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>161</fpage>
          <issue>1</issue>
          <volume>110</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Geffner</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Santulli</surname>
              <given-names>TV</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Ischii J, Kubo    M, Sumimoto T, Hamada M, Hiwada K, Kokubo T, et al. Total lipodystrophy with    heart failure and renal failure: report a case. Jpn J Med. 1989; 28: 534-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Total lipodystrophy with heart failure and renal failure: report a case</article-title>
          <source>Jpn J Med</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>534</fpage>
          <lpage>7</lpage>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ischii</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kubo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sumimoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hamada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hiwada</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kokubo</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Klar A, Hurvitz    H, Branski D, Brand A, Grosskieselstein E. Cardiomyopathy in lipodystrophy and    the specificity spillover hypothesis. Isr J Med Sci. 1993; 29 (1): 50-2.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiomyopathy in lipodystrophy and the specificity spillover hypothesis</article-title>
          <source>Isr J Med Sci</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>50</fpage>
          <lpage>2</lpage>
          <issue>1</issue>
          <volume>29</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Klar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hurvitz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Branski</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Brand</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grosskieselstein</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Rheuban KS,    Blizzard RM, Parker MA, Carter T, Wilson T, Gutgesell HP. Hypertrophic Cardiomyopathy    in total lipodystrophy. J Pediatr. 1986; 109 (2): 301-2.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hypertrophic Cardiomyopathy in total lipodystrophy</article-title>
          <source>J Pediatr</source>
          <date>
            <year>1986</year>
          </date>
          <fpage>301</fpage>
          <lpage>2</lpage>
          <issue>2</issue>
          <volume>109</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rheuban</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Blizzard</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gutgesell</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Viegas RF,    Diniz RV, Viegas TM, Lira EB, Almeida DR. Cardiac involvement in total generalized    lipodystrophy (Berardinelli- Seip syndrome). Arq Bras Cardiol. 2000; 75 (3):    243-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac involvement in total generalized lipodystrophy (Berardinelli- Seip syndrome)</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>243</fpage>
          <lpage>8</lpage>
          <issue>3</issue>
          <volume>75</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Viegas</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Diniz</surname>
              <given-names>RV</given-names>
            </name>
            <name>
              <surname>Viegas</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Lira</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. R&#234;go    AG, R&#234;go MAG, Faria CA, Baracho MF, Egito EST, Mesquita ET, et al. Altera&#231;&#245;es    cardiovasculares e metab&#243;licas da lipodistrofia generalizada cong&#234;nita    (S&#237;ndrome de Seip-Berardinelli). Rev SOCERJ. 2007; 20 (2): 1-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Altera&#231;&#245;es cardiovasculares e metab&#243;licas da lipodistrofia generalizada cong&#234;nita (S&#237;ndrome de Seip-Berardinelli)</article-title>
          <source>Rev SOCERJ</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1</fpage>
          <lpage>6</lpage>
          <issue>2</issue>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>R&#234;go</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>R&#234;go</surname>
              <given-names>MAG</given-names>
            </name>
            <name>
              <surname>Faria</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Baracho</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Egito</surname>
              <given-names>EST</given-names>
            </name>
            <name>
              <surname>Mesquita</surname>
              <given-names>ET</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Choremis KB,    Constantinides B, Kattamis CA. Congenital type of generalized lipodystrophy.    Acta Paediatr Scand. 1965; 54: 175-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Congenital type of generalized lipodystrophy</article-title>
          <source>Acta Paediatr Scand</source>
          <date>
            <year>1965</year>
          </date>
          <fpage>175</fpage>
          <lpage>9</lpage>
          <volume>54</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Choremis</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Constantinides</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kattamis</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Figueiredo    Filho PP, Costa Val A, Diamante R, Cunha CF, Lamounier JA, Le&#227;o E. Congenital    generalized lipodystrophy. J Pediatr (Rio de Janeiro). 2004; 80 (4): 333-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Congenital generalized lipodystrophy</article-title>
          <source>J Pediatr (Rio de Janeiro)</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>333</fpage>
          <lpage>6</lpage>
          <issue>4</issue>
          <volume>80</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Figueiredo Filho</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Costa Val</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Diamante</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cunha</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Lamounier</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Le&#227;o</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. DuBois D, DuBois    EF. A formula to estimate the approximate surface area if height and weight    be known. Nutrition. 1989; 5 (5): 303-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A formula to estimate the approximate surface area if height and weight be known</article-title>
          <source>Nutrition</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>303</fpage>
          <lpage>13</lpage>
          <issue>5</issue>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>DuBois</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>DuBois</surname>
              <given-names>EF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Sociedade Brasileira    de Cardiologia. I Diretriz de preven&#231;&#227;o da aterosclerose na inf&#226;ncia    e na adolesc&#234;ncia. Arq Bras Cardiol. 2005; 85 (supl 6): 3-36.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>I Diretriz de preven&#231;&#227;o da aterosclerose na inf&#226;ncia e na adolesc&#234;ncia</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>3</fpage>
          <lpage>36</lpage>
          <volume>85</volume>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Sociedade Brasileira    de Cardiologia. IV Diretriz brasileira sobre dislipidemias e preven&#231;&#227;o    da aterosclerose. Arq Bras Cardiol. 2007; 88 (supl 1): 2-19.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>IV Diretriz brasileira sobre dislipidemias e preven&#231;&#227;o da aterosclerose</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2</fpage>
          <lpage>19</lpage>
          <volume>88</volume>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation>21. Sociedade Brasileira de Diabetes. Consenso brasileiro sobre diabetes 2002: diagn&#243;stico e classifica&#231;&#227;o do diabetes melito e tratamento do diabetes melito tipo 2. Rio de Janeiro: Diagraphic; 2003.</mixed-citation>
        <element-citation publication-type="book">
          <source>diagn&#243;stico e classifica&#231;&#227;o do diabetes melito e tratamento do diabetes melito tipo 2</source>
          <date>
            <year>2003</year>
          </date>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Cook S, Auinger    P, Weitzman M. Comparison of adult definitions for metabolic syndrome in US    adolescents. Obes Res. 2004; 12: A217-A.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparison of adult definitions for metabolic syndrome in US adolescents</article-title>
          <source>Obes Res</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>A217</fpage>
          <lpage>A</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cook</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Auinger</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Weitzman</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Cleeman JI,    Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, et al. Executive summary    of the Third Report of the National Cholesterol Education Program (NCEP) expert    panel on detection, evaluation, and treatment of high blood cholesterol in adults    (Adult Treatment Panel III). JAMA. 2001; 285 (19): 2486-97.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)</article-title>
          <source>JAMA</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2486</fpage>
          <lpage>97</lpage>
          <issue>19</issue>
          <volume>285</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cleeman</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Grundy</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Denke</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Sociedade Brasileira    de Cardiologia. I Diretriz brasileira de diagn&#243;stico e tratamento da    s&#237;ndrome metab&#243;lica. Arq Bras Cardiol. 2005; 84 (supl 1): 3-28.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>I Diretriz brasileira de diagn&#243;stico e tratamento da s&#237;ndrome metab&#243;lica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>3</fpage>
          <lpage>28</lpage>
          <volume>84</volume>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. The fourth    report on the diagnosis, evaluation, and treatment of high blood pressure in    children and adolescents. Pediatrics. 2004; 114 (2): 555-76.</mixed-citation>
        <element-citation publication-type="journal">
          <source>Pediatrics</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>555</fpage>
          <lpage>76</lpage>
          <issue>2</issue>
          <volume>114</volume>
          <person-group person-group-type="author">
            <name>
              <surname>The fourth report on the diagnosis</surname>
              <given-names>evaluation, and treatment of high blood pressure in children and adolescents</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Chobanian AV,    Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh Report    of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment    of High Blood Pressure. Hypertension. 2003; 42 (6): 1206-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</article-title>
          <source>Hypertension</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1206</fpage>
          <lpage>52</lpage>
          <issue>6</issue>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chobanian</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Bakris</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Cushman</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Izzo JL</surname>
              <given-names>Jr</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Moffa PJ, Sanches    PCR. Tranchesi J. Eletrocardiograma normal e patol&#243;gico. 7&#350; ed. S&#227;o    Paulo (SP): Roca; 2001.</mixed-citation>
        <element-citation publication-type="book">
          <source>Eletrocardiograma normal e patol&#243;gico</source>
          <date>
            <year>2001</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Moffa</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Sanches</surname>
              <given-names>PCR</given-names>
            </name>
            <name>
              <surname>Tranchesi</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Juhl JH. M&#233;todos    de exame, anatomia e malforma&#231;&#245;es cong&#234;nitas do t&#243;rax.    In: Juhl JH, Crumamy AB, Kuhlman JE. Interpreta&#231;&#227;o radiol&#243;gica.    6<sup>th</sup> ed. Rio de Janeiro: Guanabara Koogan; 1996.</mixed-citation>
        <element-citation publication-type="book">
          <source>Interpreta&#231;&#227;o radiol&#243;gica</source>
          <date>
            <year>1996</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Juhl</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Juhl</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Crumamy</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Kuhlman</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Sahn D, DeMaria    A, Kissio J, Weyman A. The Committee on M-mode Standardization of American Society    of Echocardiography, "Recommendations Regarding Quantitation in M-Mode Echocardiography:    Resusts of a Survey of Echocardiographic Measurements". Circulation. 1978; 58    (6): 1072-83.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The Committee on M-mode Standardization of American Society of Echocardiography, "Recommendations Regarding Quantitation in M-Mode Echocardiography: Resusts of a Survey of Echocardiographic Measurements"</article-title>
          <source>Circulation</source>
          <date>
            <year>1978</year>
          </date>
          <fpage>1072</fpage>
          <lpage>83</lpage>
          <issue>6</issue>
          <volume>58</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sahn</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>DeMaria</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kissio</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Weyman</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Henry WL, Gardin    JM, Ware JH. Echocardiographic measurements in normal subjects from infancy    to old-age. Circulation. 1980; 62 (5): 1054-61.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Echocardiographic measurements in normal subjects from infancy to old-age</article-title>
          <source>Circulation</source>
          <date>
            <year>1980</year>
          </date>
          <fpage>1054</fpage>
          <lpage>61</lpage>
          <issue>5</issue>
          <volume>62</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Henry</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Gardin</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Ware</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Devereux RB,    Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic    assessment of left ventricular hypertrophy: comparison to necropsy findings.    Am J Cardiol. 1986; 57: 450-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1986</year>
          </date>
          <fpage>450</fpage>
          <lpage>8</lpage>
          <volume>57</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Alonso</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Lutas</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Campo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sachs</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Lang RM, Bierig    M, Devereux RB, Flachs Kampf FA, Foster E, Pellikka PA, et al. Recommendations    for chamber quantification: a report from the American Society of Echocardiography's    guidelines and standards committee and the chamber quantification writing group,    developed in conjunction with the European Association of Echocardiography,    a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;    18 (12): 1440-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1440</fpage>
          <lpage>63</lpage>
          <issue>12</issue>
          <volume>18</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lang</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Bierig</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Flachs Kampf</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pellikka</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Rakowski H,    Appleton C, Chan KL, Dumesnil JG, Honos G, Jue J, et al. Canadian consensus    recommendations for the measurement and reporting of diastolic dysfunction by    echocardiography: from the Investigators of Consensus on Diastolic Dysfunction    by Echocardiography. J Am Soc Echocardiogr. 1996; 9 (5): 736-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of Consensus on Diastolic Dysfunction by Echocardiography</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>736</fpage>
          <lpage>60</lpage>
          <issue>5</issue>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rakowski</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Appleton</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Dumesnil</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Honos</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Jue</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Crawford MH,    Bernstein SJ, Deedwania PC, Di Marco JP, Ferrick KJ, Garson A Jr, et al. ACC/AHA    Guidelines for Ambulatory Electrocardiography: a report of the American College    of Cardiology/American Heart Association Task Force on Practice Guidelines -    (Committee to revise the guidelines for ambulatory electrocardiography) - Developed    in collaboration with the North American society for pacing and electrophysiology.    J Am Coll Cardiol. 1999; 34 (3): 912-45.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>ACC/AHA Guidelines for Ambulatory Electrocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines - (Committee to revise the guidelines for ambulatory electrocardiography) - Developed in collaboration with the North American society for pacing and electrophysiology</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>912</fpage>
          <lpage>45</lpage>
          <issue>3</issue>
          <volume>34</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Crawford</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Bernstein</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Deedwania</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Di Marco</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Ferrick</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Garson A Jr</surname>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Mason RE, Likar    I, Biern RO, Ross RS. Multiple lead exercise eletrocardiography: experience    in 107 normal subject 67 patients, and comparasion with coronary cinearteriography    in 84 patients. Circulation. 1967; 36: 517.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Multiple lead exercise eletrocardiography: experience in 107 normal subject 67 patients, and comparasion with coronary cinearteriography in 84 patients</article-title>
          <source>Circulation</source>
          <date>
            <year>1967</year>
          </date>
          <fpage>517</fpage>
          <volume>36</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mason</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Likar</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Biern</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Bruce RA. Exercise    testing of patients with coronary heart disease. Ann Clin Res. 1971; 3: 323-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise testing of patients with coronary heart disease</article-title>
          <source>Ann Clin Res</source>
          <date>
            <year>1971</year>
          </date>
          <fpage>323</fpage>
          <lpage>30</lpage>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bruce</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Sociedade Brasileira    de Cardiologia. II Diretrizes sobre teste ergometrico. Arq Bras Cardiol. 2002;    78 (supl 2): 1-17.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>II Diretrizes sobre teste ergometrico</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1</fpage>
          <lpage>17</lpage>
          <volume>78</volume>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Bhayana S,    Siu VM, Joubert GI, Clarson CL, Cao H, Hegele RA. Cardiomyopathy in congenital    complete lipodystrophy. Clin Genet. 2002; 61 (4): 283-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiomyopathy in congenital complete lipodystrophy</article-title>
          <source>Clin Genet</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>283</fpage>
          <lpage>7</lpage>
          <issue>4</issue>
          <volume>61</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bhayana</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Siu</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Joubert</surname>
              <given-names>GI</given-names>
            </name>
            <name>
              <surname>Clarson</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hegele</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Westvik J.    Radiological features in generalized lipodystrophy. Acta Paediatr. 1996; 85:    44-51.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Radiological features in generalized lipodystrophy</article-title>
          <source>Acta Paediatr</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>44</fpage>
          <lpage>51</lpage>
          <volume>85</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Westvik</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Lauer MS, Okin    PM, Larson MG, Evans JC, Levy D. Impaired heart rate response to graded exercise:    prognostic implications of chronotropic incompetence in the Framingham Heart    Study. Circulation. 1996; 93 (8): 1520-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Impaired heart rate response to graded exercise: prognostic implications of chronotropic incompetence in the Framingham Heart Study</article-title>
          <source>Circulation</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>1520</fpage>
          <lpage>6</lpage>
          <issue>8</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lauer</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Okin</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Cardiometabolic abnormalities in patients with berardinelli-Seip syndrome</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Berardinelli-Seip syndrome (BSS) or Generalized Congenital Lipodystrophy often affects the cardiovascular system and also promotes metabolic abnormalities involving glycidic and lipid metabolisms. OBJECTIVE: To assess the prevalence of cardiometabolic abnormalities in patients with BSS. METHODS: Twenty-two patients from the state of Rio Grande do Norte, Brazil, diagnosed with BSS, underwent clinical evaluation, resting electrocardiogram, echodopplercardiogram, chest X-ray, 24-hour ambulatory electrocardiogram monitoring, exercise testing and laboratory analysis. RESULTS: The patients were predominantly young adults, most of whom women. The whole sample showed insulin resistance, acanthosis nigricans and diminished HDL-cholesterol. The presence of splenomegaly, hepatomegaly, type II diabetes and elevated triglycerides was constant. Metabolic syndrome was characterized in most patients, which were predominantly women and with a high degree of paternal consanguinity. SAH and prehypertension blood pressure were found in more than half of the patients (77.3%). The echodopplercardiogram showed the presence of CLVH (50%), eccentric left ventricular hypertrophy (4.5%), and normal left ventricular geometry (45.5%). High arrhythmia rates were observed by Holter monitoring, such as ventricular ectopic beats, supraventricular ectopic beats and sustained supraventricular tachycardia. Chronotropic incompetence (54.5%) was observed during exercise testing. CONCLUSION: A high prevalence of cardiovascular and metabolic abnormalities was observed in young asymptomatic individuals with BSS. These findings point to the need for systematic cardiological follow-up and of preventive measures in this high-risk group.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Lipodystrophy, Congenital Generalized</kwd>
        <kwd>Metabolism</kwd>
        <kwd>Cardiovascular Diseases</kwd>
        <kwd>Lipid Metabolism</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p><inline-formula id="top-body2"/>Cardiometabolic Abnormalities in Patients with Berardinelli-Seip Syndrome     </p>
      <p>
        <bold>Antonio Guedes do R&#234;go<sup>I</sup>; Evandro Tinoco Mesquita<sup>II</sup>; Carlos Alberto de Faria<sup>I</sup>; Marcel &#193;lvares Guedes do R&#234;go<sup>III</sup>; Maria de F&#225;tima Paiva Baracho<sup>I</sup>; Maria Goretti do Nascimento Santos<sup>I</sup>; Eryvaldo S&#243;crates Tabosa do Egito<sup>I</sup>; Jos&#233; Brand&#227;o Neto<sup>I</sup></bold>
      </p>
      <p><sup>I</sup>Universidade Federal do Rio Grande do Norte (UFRN)</p>
      <p><sup>II</sup>Natal, RN; Universidade Federal Fluminense (UFF)</p>
      <p><sup>III</sup>Niter&#243;i, RJ; CLINICOR, Natal, RN, Brasil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Berardinelli-Seip syndrome (BSS) or Generalized Congenital Lipodystrophy often affects the cardiovascular system and also promotes metabolic abnormalities involving glycidic and lipid metabolisms.</p>
      <p><bold>OBJECTIVE: </bold> To assess the prevalence of cardiometabolic abnormalities in patients with BSS.</p>
      <p><bold>METHODS: </bold> Twenty-two patients from the state of Rio Grande do Norte, Brazil, diagnosed with BSS, underwent clinical evaluation, resting electrocardiogram, echodopplercardiogram, chest X-ray, 24-hour ambulatory electrocardiogram monitoring, exercise testing and laboratory analysis.</p>
      <p><bold>RESULTS: </bold> The patients were predominantly young adults, most of whom women. The whole sample showed insulin resistance, <italic>acanthosis nigricans</italic> and diminished HDL-cholesterol. The presence of splenomegaly, hepatomegaly, type II diabetes and elevated triglycerides was constant. Metabolic syndrome was characterized in most patients, which were predominantly women and with a high degree of paternal consanguinity. SAH and prehypertension blood pressure were found in more than half of the patients (77.3%). The echodopplercardiogram showed the presence of CLVH (50%), eccentric left ventricular hypertrophy (4.5%), and normal left ventricular geometry (45.5%). High arrhythmia rates were observed by Holter monitoring, such as ventricular ectopic beats, supraventricular ectopic beats and sustained supraventricular tachycardia. Chronotropic incompetence (54.5%) was observed during exercise testing.</p>
      <p><bold>CONCLUSION:</bold> A high prevalence of cardiovascular and metabolic abnormalities was observed in young asymptomatic individuals with BSS. These findings point to the need for systematic cardiological follow-up and of preventive measures in this high-risk group.</p>
      <p><bold>Key Words:</bold> Lipodystrophy, Congenital Generalized; Metabolism / Genetics; Cardiovascular Diseases / Genetics; Lipid Metabolism / Genetics.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>BSS or generalized congenital lipodystrophy was described for the first time in Brazil by Berardinelli et al. in 1954<sup>1</sup>, in two children<sup>1</sup>. In 1959 Seip et al<sup>2</sup>, described this same syndrome in three other patients<sup>2</sup>. BSS has a genetic character with recessive autosomal transmission, and often paternal consanguinity of indeterminate cause, due to mutation in AGPAT2 and Gng3lg<sup>3</sup>. Two loci are described: BSCL1 and BSCL2 in BSS, in chromosomes 9q34 and 11q13, respectively<sup>3</sup>. In a study carried out with 21 patients from Rio Grande do Norte, Brazil, mutation was found in the Gng3lg of 19 individuals and in the AGPAT2<sup>4</sup> of two subjects.</p>
      <p>BSS is rare syndrome, with a prevalence of one case per ten million people<sup>3</sup> . The individuals affected present with nonketotic, insulant-resistant type II diabetes, accompanied by the almost total absence of subcutaneous adipose tissue. Diagnosis can be established at birth or during childhood and is characterized by clinical, metabolic and laboratory alterations which include the following: absence or decrease of subcutaneous fat tissue; accelerated growth with acromegaloid pattern; and accentuated somatic and skeletal development. The presence of hepatomegaly is common, owing to fat infiltration that may evolve to cirrhosis, splenomegaly, acanthosis nigricans, macroglossia, gynecomastia, hyperglycemia hypertriglyceridemia, hyperinsulinemia, decreased levels of HDL-cholesterol (HDL-c); sometimes accompanied by elevated total cholesterol (C-t) and LDL-cholesterol (LDL-c). The serum levels of leptin and adiponectin are extremely low<sup>3,5,6</sup>.</p>
      <p>There are few published articles on cardiac alterations as a consequence of BSS. There are fewer than twenty reports on cardiac alterations, with sample size not exceeding 10 patients<sup>7-14</sup>. These studies showed that the most frequent cardiovascular alterations were cardiac hypertrophy; cardiomegaly and hypertrophic cardiomyopaty; particularly asymetric septal hypertrophy; left ventricular dysfunction; and systemic arterial hypertension (SAH)<sup>7-17</sup>. There is only one case report in Brazil in which cardiac alterations were described<sup>14</sup>.</p>
      <p>The objective of this study was to determine cardiovascular and metabolic abnormalities in patients with BSS, using clinical evaluation, biochemical tests, resting electrocardiogram (ECG), chest X-ray, exercise testing, echodopplercardiogram and 24-hour ambulatory ECG monitoring (Holter).</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>
        <bold>Subjects</bold>
      </p>
      <p>In total, 22 patients with BSS from the state of Rio Grande do Norte, Brazil, were treated at the Endocrinology, Metabology and Cardiology outpatient facility of Onofre Lopes University Hospital (HUOL) at the Universidade Federal do Rio Grande do Norte (UFRN). Each patient or their legal representative signed the free informed consent , which was previously approved by the Institution's Research Ethics Committee (Protocol no. 42/2003). All examinations were conducted on the same day and none of the patients had taken any medication for at least 5 days.</p>
      <p><italic>Clinical parameters</italic> - A protocol for each patient was filled out, containing personal data, anamnesis and general clinical examination, endocrinological and cardiovascular findings. All examinations were performed by specialized physicians.</p>
      <p><italic>Anthropometric assessment -</italic> Weight was measured three times on a digital scale (Balmark, S&#227;o Paulo, SP, Brazil), with a maximum capacity of 160 kg and accurate to 100 g. Waist circunference (WC) was measured on an imaginary horizontal line that passed through the middle point between the lower edge of the last rib and the iliac crest. Body surface area (BSA) was calculated by the DuBois and DuBois equation<sup>18</sup>. Measures of weight and height were used to calculate body mass index (BMI). Children with BMI &gt; 95 percentile were considered obese and those with BMI between percentiles 85 and 95 as overweight<sup>19</sup> . For the adults, BMI was considered normal when it was between 18.5- and 24.9 kg/m&#178;; overweight between 25.0 and 29.9 kg/m&#178; and obese &gt;30 kg/m&#178; <sup>20</sup>.</p>
      <p><italic>Biochemical parameters -</italic> Five mL of total blood was collected after a 12h fast. Fasting glucose, C-t, HDL-c and triglycerides (TG) were assessed. Low-density lipoprotein cholesterol (LDL-c) was not calculated because it becomes progressively less accurate with increasing serum TG concentrations and is not used for metabolic syndrome (MS) criteria<sup>20</sup>. The dosages were determined in a biochemical analyzer (Chem Well, Palm City, FL, USA) using specific reagents (Labtest, Minas Gerais, Brasil).</p>
      <p><italic>Criteria and guidelines -</italic> Normality criteria, defined by the I Guidelines for the Prevention of Atherosclerosis in Childhood<sup>19</sup>, by the IV Guidelines for the Prevention of Atherosclerosis of the Brazilian Cardiology Society<sup>20</sup> and by the Brazilian Consensus on Diabetes<sup>21</sup>, were adopted. Information on the insulin resistance of each individual was obtained from HUOL patient records.</p>
      <p>To assess MS criteria in adolescents and children, NCEP/ATP III<sup>22</sup> norms were adopted, modified for age and requiring the presence of at least 3 of 5 parameters as follows: TG levels <underline>&gt;</underline> 110 mg/dL; HDL-c <underline>&lt;</underline> 40 mg/dL; WC <underline>&gt;</underline> 90 percentile according to sex and age; glycemia <underline>&gt;</underline> 110 mg/dL; and systolic or diastolic blood pressure (SBP or DBP) <underline>&gt;</underline> 90 percentile according to sex, age and height. On the other hand, according to NCEP/ATP III<sup>23</sup>, for adults MS represents the combination of at least three of the following components: abdominal obesity using WC (men &gt; 102 cm and women &gt; 88 cm); TG <underline>&gt;</underline>150 mg/dL: HDL-c for men &lt; 40 mg/dL and for women &lt; 50 mg/dL; arterial blood pressure <underline>&gt;</underline> 130 mmHg or <underline>&gt;</underline> 85 mmHg; and fasting glucose <underline>&gt;</underline> 110 mg/dL. The presence of type II diabetes mellitus does not rule out the diagnosis of MS. Owing to its simplicity and practicality, this is the definition recommended by the I Brazilian Guidelines for the Diagnosis and Treatment of Metabolic Syndrome<sup>24</sup>.</p>
      <p><italic>Hemodynamic parameters -</italic> Arterial blood pressure (ABP) was measured by the indirect method, using a blood pressure monitor (Welch Allyn, Skaneateles Falls, NY, USA), graduated and calibrated from zero to 300 mmHg. Three measures were taken after a five-minute rest period with the patient in the sitting position. The measuring procedures and arterial pressure classification were conducted according to The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High blood Pressure<sup>25,26</sup>. The ABP values were not rounded off for digits ending in five or zero.</p>
      <p><italic>Electrocardiogram</italic> - The ECG, performed after a 10-minute rest period, was recorded on an electrocardiographic recording system (Cardioline Delta Plus, Cavareno, Trento, Italy) with 12 derivations. The graphic record was standardized at a velocity of 25mm/s and the device was calibrated with an amplitude of 1 mV, corresponding to 10 mm on the vertical axis<sup>27</sup>. Final assessment was carried out by two cardiologists; since there was a disagreement between the two results, a third professional determined the final result of the examination.</p>
      <p><italic>Chest X-ray-</italic> The chest X-ray was taken by a device (Emic, Modelo MKTE 500, S&#227;o Paulo, SP-Brasil) equipped with an Agfa Cr 75.0 (Mortsel-Belgium) digital processing system at maximum inspiration. For the children that were unable to maintain maximum inspiration, the examination was performed at a distance of 1 m, generally in the anterior-posterior projection. In the adults the distance was between 1.75 and 2 m in anterior-posterior projection and left profile. Using this technique, we assessed the cardiac area according to the cardiothoracic index and the pleuropulmonary evaluation, as well as the diaphragm dome<sup>28</sup>.</p>
      <p><italic>Echodopplercardiogram -</italic> This examination was uni- and bidimensional with pulsed and continuous Doppler using color flow imaging (Hewlett Packard, Model 2410 A-Ultrasound System, Andover-MA, USA). Five measures were taken for each variable studied and the mean final value was considered for analysis. The device contained 2.5 and 5.0 mHz transductors that enabled M-mode and bidimensional assessment with pulsed and continuous Doppler. The images and cardiac dimensions were obtained according to American Society of Echocardiography (ASE) recommendations<sup>29,30</sup>, from conventional echocardiographic cuts.</p>
      <p>To calculate left ventricular mass (LVM), the formula recommended by the ASE and corrected by the Penn convention<sup>31</sup> was adopted. The left ventricular mass index (LVMI) was calculated by correcting the value of mass (g) by BSA (m&#178;). An LVMI less than or equal to 95 g/m&#178; and 115g/m&#178; was considered normal for women and men, respectively<sup>32</sup>. The calculation of relative wall thickness (RWT) was obtained by the following formula:</p>
      <p>RWT = (2 x PWTd) / LVId</p>
      <p>Where PWTd and LVId are posterior wall thickness at the end of diastole and left ventricular end diastolic dimension, respectively.</p>
      <p>The patients were classified into four groups of cardiac geometry<sup>32</sup>:</p>
      <p>a) Normal geometry = normal LVMI and RWT <underline>&lt;</underline> 0.42;</p>
      <p>b) Concentric remodeling = normal LVMI and RWT &gt; 0.42;</p>
      <p>c) Concentric hypertrophy = increased LVMI and RWT &gt; 0.42;</p>
      <p>d) Eccentric hypertrophy = increased LVMI and RWT <underline>&lt;</underline> 0.42.</p>
      <p>The ejection fraction (EF) was calculated by Simpson's method from an apical four-chamber view <sup>32</sup>. Values <underline>&gt;</underline> 55% were considered normal.</p>
      <p>Assessment of intracardiac flow patterns followed the guidelines of the Canadian Consensus and served to evaluate LV diastolic function<sup>33</sup>. The following variables were obtained:</p>
      <p>a) Peak mitral E-wave velocity (m/s);</p>
      <p>b) Peak mitral A-wave velocity (m/s);</p>
      <p>c) E/A ratio;</p>
      <p>d) Mitral Deceleration Time in m/s corresponding to the time interval between the E-wave peak and its extrapolation to baseline;</p>
      <p>e) Left Ventricular Isovolumic Relaxation Time (IVRT) in m/s, corresponding to the interval from aortic valve closure to mitral valve opening.</p>
      <p>The first three variables were obtained before and during the strain phase of the Valsalva maneuver.</p>
      <p>24-hour ambulatory electrocardiogram monitoring (Holter) - The patients were monitored for 24 hours, using a 3-channel digital recorder (Cardioflash Digital Cardios, S&#227;o Paulo-SP, Brazil). Preparation, the examination, analysis and the report followed ACC/AHA Guidelines for Ambulatory Eletrocardiography<sup>34</sup>.</p>
      <p><italic>Exercise testing</italic> - was carried out on a treadmill (IMBRAMED, Model Soft Move I, Porto Alegre-RS, Brazil). The patients were prepared for continuous EGG monitoring, using the modified derivations of Mason et al<sup>35</sup>. The examination was initiated using the Bruce protocol<sup>36</sup>. The examination, aimed at assessing clinical, electrocardiographic and hemodynamic responses, and thus followed guidelines for reliable, reproducible and measurable results contained in the II Directive of the Brazilian Society of Cardiology on the Ergometric Test<sup>37</sup>.</p>
      <p><italic>Statistical analysis -</italic> The comparison between the two subgroups was analyzed by the Mann-Whitney test for numerical data and by Fisher's exact test for categorical data (qualitative). The numerical data were summarized and expressed as mean and standard deviation, and the qualitative data as frequency (n) and percentage (%). The Mann-Whitney nonparametric test was used, since the variables did not show normal distribution (Gaussian), owing to the lack of distribution symmetry and mainly because of the small sample size in the subgroups studied. The significance level was set at 5%. Statistical analysis was processed by SAS software 6.04 (SAS Institute, Inc., Cary, North Carolina, USA).</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>
        <bold>Subjects</bold>
      </p>
      <p>The clinical characteristics of the 22 patients studied are shown in <xref ref-type="fig" rid="f1-body2">figure 1</xref> and <xref ref-type="table" rid="en_17t01-body2">table1</xref>.</p>
      <p content-type="asset">
        <table-wrap id="en_17t01-body2">
          <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt01-en.jpg"/></table-wrap>
      </p>
      <fig id="f1-body2">
        <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gf01-en.jpg"/></fig>
      <p>
        <bold>Clinical parameters</bold>
      </p>
      <p><xref ref-type="table" rid="en_17t01-body2">Table 1</xref> also describes the clinical parameters. A family history of BSS was identified in 86.4% of the patients, with a predominance in women (92.9%) because of their greater number. Type II diabetes mellitus occurred in 68.2% of the patients, 62.5% of which were men. Insulin resistance and <italic>acanthosis nigricans</italic> was diagnosed in all the patients. MS occurred in 81.8% of the cases, with a similar prevalence between genders. Hepatomegaly occurred in 90.9% of the patients, with no difference between genders, and splenomegaly in 45.5%, with a predominance in women.</p>
      <p>
        <bold>Antropometric assessment</bold>
      </p>
      <p>The anthropometric characteristics of the 22 patients studied are shown in <xref ref-type="table" rid="en_17t01-body2">table 1</xref>. Mean age was 22.4 &#177; 9.7 years, with no statistical difference between genders. Mean weight was 56.6 &#177; 15.1 kg and higher in the men (p=0.003). BMI showed a mean of 21.6 &#177; 3.3, also higher in the men (p=0.001). Mean BSA was 1.58 &#177; 0.27 and more elevated in the men (p=0.004). WC showed a mean of 82 &#177; 9.2, and was significantly higher in the men (p=0.011).</p>
      <p>
        <bold>Biochemical parameters</bold>
      </p>
      <p>Fasting glucose remained high (177.8 &#177; 84.4, with no significant difference between genders. Mean C-t was 175.4 &#177; 38.1, also with no significant difference between genders. Mean HDL-c was 27.4 &#177; 7.7, and higher in the women (p=0.033). The TGs remained high (331.7 &#177; 286.4), although with no significant difference between genders (<xref ref-type="table" rid="en_17t01-body2">table 1</xref>).</p>
      <p>
        <bold>Arterial blood pressure</bold>
      </p>
      <p>Basal heart rate, with a mean of 91.6 &#177; 8.3, was higher in the women (p=036). SAH occurred in 50% and prehypertension in 27.3% of BSS patients (<xref ref-type="table" rid="en_17t01-body2">table 1</xref>). The means of SBP and DBP were higher in both genders, although not statistically different.</p>
      <p>
        <bold>Basal electrocardiogram</bold>
      </p>
      <p>All the patients with BSS showed sinus rhythm; 18.2% had left ventricular hypertrophy (LVH) and 3.6% had alterations in ventricular repolarization. Other alterations were irrelevant (data not shown).</p>
      <p>
        <bold>Chest X-ray</bold>
      </p>
      <p>Of the 22 patients with BSS, 95.5% had normal chest X-ray. Only one woman showed an increased heart area and pulmonary flow inversion to the apexes (data not shown).</p>
      <p>
        <bold>Echodopplercardiogram</bold>
      </p>
      <p><xref ref-type="table" rid="en_17t02-body2">Table 2</xref> shows that the echodopplercardiogram was normal in 40.9% of the patients, with no statistical significance between genders. Mild mitral regurgitation appeared in 27.3% of the BSS patients, predominantly in women. Calcification of the aortic valve was diagnosed in 9.1% of the patients and mild aortic regurgitation in 4.5%, all of whom were women. Concentric left ventricular hypertrophy (CLVH) was found in around 50% of the patients from both genders and eccentric left ventricular hypertrophy in 4.5% (predominantly women). Normal left ventricular geometry was present in 45.5% of the cases studied, practically equal in men and women. The patterns of left ventricular diastolic function assessed by transmitral flow were within normal limits, before and during the strain phase of the Valsalva maneuver (<xref ref-type="table" rid="en_17t02-body2">table 2</xref>). Left ventricular systolic function was assessed by ejection fraction (Simpson), which had a mean value of 67.3%, with no difference between genders.</p>
      <p content-type="asset">
        <table-wrap id="en_17t02-body2">
          <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt02-en.jpg"/></table-wrap>
      </p>
      <p><xref ref-type="table" rid="en_17t03-body2">Table 3</xref> relates the frequency and percentage of LVH in the electrocardiogram and clinical parameters to the echodopplercardiogram (normal or abnormal). LVH in the ECG (30.8%), diabetes mellitus (76.9%), hepatomegaly (100%), splenomegaly (61.5%), and SAH plus prehypertension (92.3%) were more present in the abnormal echodopplercardiogram.</p>
      <p content-type="asset">
        <table-wrap id="en_17t03-body2">
          <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt03-en.jpg"/></table-wrap>
      </p>
      <p><xref ref-type="table" rid="en_17t04-body2">Table 4</xref> relates the frequency and percentage of various clinical parameters and LVH in the electrocardiogram to CLVH in the echocardiogram. Among the eletrocardiographic parameters, 36.4% of LVH was detected only in the presence of CLVH. The most frequent clinical parameters, such as diabetes mellitus (72.7%), hepatomegaly (100%), splenomegaly (63.6%), and SAH plus prehypertension (90.9%) were more observed in the presence of CLVH than in its absence.</p>
      <p content-type="asset">
        <table-wrap id="en_17t04-body2">
          <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt04-en.jpg"/></table-wrap>
      </p>
      <p>
        <bold>24-hour ambulatory electrocardiogram monitoring (Holter)</bold>
      </p>
      <p><xref ref-type="table" rid="en_17t05-body2">Table 5</xref> shows the association between arrhythmias determined by Holter and chronotropic incompetence found in exercise testing (ET) compared to CLVH observed on the echocardiogram of 22 patients with BSS. Patients with normal Holter had CLVH present (18.2%) and absent (36.4%), with no significance between the two groups. Ventricular ectopic beats were equally detected in 54.6% of patients with CLVH present and absent. Patients with supraventicular ectopic beats had a percentage of 81.8% associated to CLVH present and 54.6% to CLVH absent. Sustained supraventricular tachycardia was detected in 27.3% of the patients with CLVH present and 9.1% with CLVH absent.</p>
      <p content-type="asset">
        <table-wrap id="en_17t05-body2">
          <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt05-en.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Exercise testing</bold>
      </p>
      <p>Chronotropic incompetence was observed in ET in 45.5% of the patients with CLVH present and in 63.6% with CLVH absent, with no statistical difference (<xref ref-type="table" rid="en_17t05-body2">table 5</xref>).</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>To date, BSS has been described in fewer than 300 patients. The current literature suggests that only 1 in 4 cases is reported, which enables an estimate of the disease at around 1 case per 10 million inhabitants<sup>3</sup>. The state of Rio Grande do Norte (Brazil) has a population estimated at 3 million inhabitants. Therefore, our group represents a significant sample, being sample size the largest in the world.</p>
      <p>The occurrence of cardiovascular and metabolic abnormalities in patients with BSS is currently little discussed. In this study, the prevalence of paternal consanguinity; type II diabetes mellitus; insulin resistance; <italic>acanthosis nigricans</italic>; hepatomegaly; splenomegaly; decreased HDL-c; and increased TG was similar to those found in the literature (<xref ref-type="table" rid="en_17t01-body2">table1</xref>)<sup>3, 6,10,11,14,15,17</sup>.</p>
      <p>A relevant finding of this study was that MS was identified for the first time in patients with BSS. It was found in most of the patients: 18 (81.8%), 11 (78.6%) of whom were female. Of the 7 (31.81%) children and adolescents in this study, 6 had criteria for MS, 5 (71.42%) of whom were female and 1 (14.28%) male. The most prevalent criteria were low HDL-c (81.81%); hyperglycemia (77.27%); hypertriglyceridemia (63.63%); and SAH (50%). With respect to WC none of the patients showed an increase in this variable. The male patients had higher WC than the females, which results in higher preventive care in regard to cardiopathies (<xref ref-type="table" rid="en_17t01-body2">table 1</xref>). These findings were quite significant owing to the high incidence found in BSS and because they are representative of the increase in general mortality and in cardiovascular complications<sup>24</sup>.</p>
      <p>All patients showed poor control over fasting glucose, in addition to decreased HDL-c and increased TG. These results were similar to those found in the literature (<xref ref-type="table" rid="en_17t01-body2">table 1</xref>)<sup>3,6,10,11,14,15,17</sup>. The association between low HDL-c and elevated TG greatly increase the risk factors for cardiovascular diseases<sup>24</sup>.</p>
      <p>SAH was observed in 50% of the patients. These findings are in complete agreement with other authors who found it in 46.5% of the 13 case reports studied<sup>2,8,16</sup>. Prehypertension, not previously described, was identified in 27.3% of the patients. (<xref ref-type="table" rid="en_17t01-body2">table 1</xref>). This classification of prehypertension is particularly important for treating patients with MS and diabetes mellitus<sup>24,26</sup>.</p>
      <p>Another relevant finding from this study is related to the results obtained with the electrocardiogram and the chest X-ray. Neither of these parameters was useful in identifying the presence of cardiac abnormalities in BSS, particularly the presence of LVH. Unlike other studies, which often found cardiomegaly in chest-X-rays<sup>7,8,11,13,16</sup>, only 1 case was observed in the present work (datum not shown). Therefore, to identify cardiovascular damage, an echodopplercardiographic study was indispensable.</p>
      <p>With respect to the echocardiographic abnormalities in this study, a high prevalence of cardiac damage was found, through the presence of CLVH (50%) in both genders, a finding similar to that of other authors<sup>7,8,14,15,17</sup>. On the other hand, no case of hypertrophic cardiomyopathy was detected, although it has been widely reported in the literature as a frequent finding<sup>6-8,11-13,15,38</sup>. Eccentric left ventricular hypertrophy was observed in 4.5% of the patients. Mild mitral regurgitation was found in 6 patients with BSS. Only 1 patient showed global left ventricular hypokinesis and systolic dysfunction (<xref ref-type="table" rid="en_17t02-body2">table 2</xref>).</p>
      <p>
        <bold>Insulin resistance and cardiopathies</bold>
      </p>
      <p>The possibility of insulin resistance causing myocyte hypertrophy is the likely histopathologic link, given the increased fiber diameters and absence of criteria for hypertrophic cardiomiopaty. Indeed, this cardiomyopathy occurs in patients with insulin resistance syndrome through the direct action of insulin on insulin-like growth factor (IGF-1) receptors<sup>10</sup>. The high frequency of this pathology, associated to concentric hypertrophy in these patients was also reported by Klar et al<sup>12</sup> in 1993. In autopsy findings, the fibers were arranged without glycogen deposits and fat infiltration<sup>8,13</sup>. Hypertrophic cardiomyopathy associated to diabetes melitus is often linked to ventricular dilation and coronary artery alterations<sup>13</sup>. In the present study, only 1 patient was found with increased inner LV diameters (eccentric hypertrophy) (<xref ref-type="table" rid="en_17t02-body2">table 2</xref>). The histologic differentiation with classical hypertrophic cardiomiopaty is due to the absence of fiber disarrangement in lipodystrophy-associated hypertrophy<sup>12,14</sup>.</p>
      <p>Unlike other studies that identified high rates of diastolic dysfunction through the assessment of transmitral flow<sup>7,8,13,14</sup>, no left ventricular diastolic dysfunction was found in any of our patients, even after the Valsalva maneuver was used. Another finding that differed from the literature<sup>8,11,15,38,39</sup> was the presence of systolic dysfunction. Only 1 patient in this study had left ventricular systolic dysfunction. One of the limitations of this work was the non-use of tissue Doppler imaging, which is as yet unavailable at our facility.</p>
      <p>Holter recordings identified high rates of cardiac arrhythmia in patients with BSS. Despite the low mean age (22.4% &#177; 9.7 years) of these patients, 54.6% exhibited ventricular ectopic beats with CLVH present, and another 54.6% with CLVH absent (<xref ref-type="table" rid="en_17t05-body2">table 5</xref>). There is only one report in the literature: a 5-year-old patient, who was monitored for 24 hours, showing normal Holter<sup>38</sup>.</p>
      <p>With respect to exercise testing, chronotropic incompetence was observed in 45.5% of the patients with CLVH present and in 63.6% of patients with CLVH absent (<xref ref-type="table" rid="en_17t05-body2">table 5</xref>). Exercise testing was normal for myocardial ischemia in the patients who attained the desired heart rate and in those who displayed chronotropic incompetence. There was no relationship between chronotropic incompetence and CLVH present or absent. The presence of chronotropic incompetence is a predictor of increased cardiac mortality and incipient coronary disease, given that the desired heart rate is not achieved<sup>40</sup>. The significant relevance of this finding lies in the fact that there are no reports in the literature correlating exercise testing and chronotropic incompetence in patients with this syndrome.</p>
      <p>Finally, sudden death is reported in the few cases with cardiac alterations. The relationship between cardiac alterations and dyslipidemia is described as a cause of sudden death in BSS<sup>8,12</sup>. Cardiac alterations increase with age<sup>7,8</sup>, a finding not corroborated in the present study.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>The results obtained reveal cardiovascular and metabolic abnormalities, with a high prevalence in young, asymptomatic patients with BSS. These findings point to the need for cardiological follow-up and preventive measures in this high-risk group.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>This study was partially financied by the MCT/FINEP/SINTEC, 01/2003.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of Doctoral submitted by Ant&#244;nio Guedes do R&#234;go, from Universidade Federal do Rio Grande do Norte (UFRN).</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Anormalidades cardiovasculares y metab&#243;licas en pacientes con el s&#237;ndrome de Berardinelli-Seip</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: El s&#237;ndrome de Berardinelli-Seip (SBS) o lipodistrofia generalizada cong&#233;nita, afecta frecuentemente el aparato cardiovascular y tambi&#233;n promueve anormalidades metab&#243;licas que involucran los metabolismos gluc&#237;dico y lip&#237;dico. OBJETIVO: Evaluar la prevalencia de las anormalidades cardiovasculares y metab&#243;licas en portadores de SBS. M&#201;TODOS: Veintid&#243;s pacientes del Estado de Rio Grande do Norte (Brasil), con diagn&#243;stico de SBS, se sometieron a evaluaci&#243;n cl&#237;nica, electrocardiograma de reposo, ecocardiograma doppler, radiograf&#237;a de t&#243;rax, electrocardiograf&#237;a din&#225;mica de 24 horas, ergometr&#237;a y an&#225;lisis de laboratorio. RESULTADOS: Los pacientes eran, predominantemente, adultos j&#243;venes, siendo en su mayor&#237;a del sexo femenino. La totalidad de la muestra present&#243; resistencia a la insulina, acanthosis nigricans y HDL-colesterol disminuido. La presencia de esplenomegalia, hepatomegalia, diabetes mellitus tipo II y triglic&#233;ridos elevados era constante. El s&#237;ndrome metab&#243;lico se caracteriz&#243; en la mayor&#237;a de los pacientes, con predominancia en el sexo femenino y con un alto grado de consanguinidad paterna. En m&#225;s de la mitad de los pacientes (77,3%) se encontraron hipertensi&#243;n arterial sist&#233;mica y la prehipertensi&#243;n. El ecocardiograma Doppler mostr&#243; presencia de hipertrofia conc&#233;ntrica del ventr&#237;culo izquierdo (50%), hipertrofia exc&#233;ntrica del ventr&#237;culo izquierdo (4,5%) y geometr&#237;a normal del ventr&#237;culo izquierdo (45,5%). Se evidenci&#243; tasa elevada de arritmia en el holter, tales como extras&#237;stoles ventriculares, extras&#237;stoles supraventriculares y taquicardia supraventricular sostenida. La incompetencia cronotr&#243;pica (54,5%) se observ&#243; en la ergometr&#237;a. CONCLUSI&#211;N: Anormalidades cardiovasculares y metab&#243;licas se observaron en elevada prevalencia en individuos j&#243;venes y asintom&#225;ticos con SBS. Estos hallazgos se&#241;alan la necesidad de seguimiento cardiol&#243;gico sistem&#225;tico y de medidas preventivas en este grupo de riesgo.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Lipodistrofia generalizada cong&#233;nita</kwd>
        <kwd>enfermedades cardiovasculares</kwd>
        <kwd>metabolismo</kwd>
        <kwd>metabolismo de los l&#237;pidos</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Anormalidades cardiovasculares y metab&#243;licas en pacientes con el s&#237;ndrome de Berardinelli-Seip</bold>
          </label>
          <p>
            <bold>Antonio Guedes do R&#234;go<sup>I</sup>; Evandro Tinoco Mesquita<sup>II</sup>; Carlos Alberto de Faria<sup>I</sup>; Marcel &#193;lvares Guedes do R&#234;go<sup>III</sup>; Maria de F&#225;tima Paiva Baracho<sup>I</sup>; Maria Goretti do Nascimento Santos<sup>I</sup>; Eryvaldo S&#243;crates Tabosa do Egito<sup>I</sup>; Jos&#233; Brand&#227;o Neto<sup>I</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Universidade Federal do Rio Grande do Norte (UFRN), Natal, RN - Brasil</p>
      <p><sup>II</sup>Universidade Federal Fluminense (UFF), Niter&#243;i, RJ - Brasil</p>
      <p><sup>III</sup>CLINICOR, Natal, RN - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO: </bold> El s&#237;ndrome de Berardinelli-Seip (SBS) o lipodistrofia generalizada cong&#233;nita, afecta frecuentemente el aparato cardiovascular y tambi&#233;n promueve anormalidades metab&#243;licas que involucran los metabolismos gluc&#237;dico y lip&#237;dico.</p>
      <p><bold>OBJETIVO: </bold> Evaluar la prevalencia de las anormalidades cardiovasculares y metab&#243;licas en portadores de SBS.</p>
      <p><bold>M&#201;TODOS: </bold> Veintid&#243;s pacientes del Estado de Rio Grande do Norte (Brasil), con diagn&#243;stico de SBS, se sometieron a evaluaci&#243;n cl&#237;nica, electrocardiograma de reposo, ecocardiograma doppler, radiograf&#237;a de t&#243;rax, electrocardiograf&#237;a din&#225;mica de 24 horas, ergometr&#237;a y an&#225;lisis de laboratorio.</p>
      <p><bold>RESULTADOS: </bold> Los pacientes eran, predominantemente, adultos j&#243;venes, siendo en su mayor&#237;a del sexo femenino. La totalidad de la muestra present&#243; resistencia a la insulina, acanthosis nigricans y HDL-colesterol disminuido. La presencia de esplenomegalia, hepatomegalia, diabetes mellitus tipo II y triglic&#233;ridos elevados era constante. El s&#237;ndrome metab&#243;lico se caracteriz&#243; en la mayor&#237;a de los pacientes, con predominancia en el sexo femenino y con un alto grado de consanguinidad paterna. En m&#225;s de la mitad de los pacientes (77,3%) se encontraron hipertensi&#243;n arterial sist&#233;mica y la prehipertensi&#243;n. El ecocardiograma Doppler mostr&#243; presencia de hipertrofia conc&#233;ntrica del ventr&#237;culo izquierdo (50%), hipertrofia exc&#233;ntrica del ventr&#237;culo izquierdo (4,5%) y geometr&#237;a normal del ventr&#237;culo izquierdo (45,5%). Se evidenci&#243; tasa elevada de arritmia en el holter, tales como extras&#237;stoles ventriculares, extras&#237;stoles supraventriculares y taquicardia supraventricular sostenida. La incompetencia cronotr&#243;pica (54,5%) se observ&#243; en la ergometr&#237;a.</p>
      <p><bold>CONCLUSI&#211;N: </bold> Anormalidades cardiovasculares y metab&#243;licas se observaron en elevada prevalencia en individuos j&#243;venes y asintom&#225;ticos con SBS. Estos hallazgos se&#241;alan la necesidad de seguimiento cardiol&#243;gico sistem&#225;tico y de medidas preventivas en este grupo de riesgo. (Arq Bras Cardiol 2010; 94(1) : 103-111)</p>
      <p><bold>Palabras clave: </bold> Lipodistrofia generalizada cong&#233;nita, enfermedades cardiovasculares/gen&#233;tica, metabolismo/gen&#233;tica, metabolismo de los l&#237;pidos/gen&#233;tica.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>El s&#237;ndrome de Berardinelli-Seip (SBS) o lipodistrofia generalizada cong&#233;nita fue descrita por primera vez en Brasil por Berardinelli et al en 1954, en dos ni&#241;os<sup>1</sup>. Seip et al<sup>2</sup>, en 1959, describieron este s&#237;ndrome en tres pacientes m&#225;s<sup>2</sup>. El SBS tiene un car&#225;cter gen&#233;tico con transmisi&#243;n autos&#243;mica recesiva y frecuente consaguinidad paterna, de causa indeterminada, debido a la mutaci&#243;n en AGPAT2 y Gng3lg<sup>3</sup>. Est&#225;n descritos dos <italic>loci</italic>, BSCL1 y BSCL2 en el SBS, en los cromosomas 9q34 y 11q13, respectivamente<sup>3</sup>. En un estudio realizado en 21 de los pacientes de Rio Grande do Norte (Brasil), se encontr&#243; mutaci&#243;n en el Gng3lg en 19 individuos y en el AGPAT2<sup>4</sup> en dos.</p>
      <p>El SBS es un s&#237;ndrome raro con prevalencia de un caso en diez millones de personas<sup>3</sup>. Los individuos afectados con tal s&#237;ndrome se caracterizan por presentar <italic>diabetes mellitus</italic> tipo II, no cet&#243;tico e resistente a la insulina, acompa&#241;ada de ausencia casi completa de tejido adiposo subcut&#225;neo. El diagn&#243;stico puede ser establecido al nacer o durante la infancia y se caracteriza por alteraciones cl&#237;nicas, metab&#243;licas y de laboratorio que incluyen: Disminuci&#243;n o ausencia de tejido adiposo subcut&#225;neo, crecimiento acelerado con patr&#243;n acromegaloide, desarrollo som&#225;tico y esquel&#233;tico acentuado. Es com&#250;n la presencia de hepatomegalia debido a la infiltraci&#243;n de grasa que puede evolucionar para cirrosis, esplenomegalia, <italic>acanthosis nigricans</italic>, macroglosia, ginecomastia, hiperglicemia, hipertrigliceridemia, hiperinsulinemia, niveles reducidos de colesterol de lipoprote&#237;na de alta densidad (HDL-c), pudiendo adem&#225;s haber elevaci&#243;n del (C-t) y del colesterol de lipoprote&#237;na de baja densidad (LDL-c). Los niveles s&#233;ricos de leptina y adinopectina son extremadamente bajos<sup>3,5,6</sup>.</p>
      <p>Hay pocos estudios publicados en la bibliograf&#237;a sobre alteraciones card&#237;acas derivadas de la SBS. Menos de veinte relatos informaron alteraciones card&#237;acas, con casu&#237;stica inferior a diez pacientes<sup>7-14</sup>. Tales estudios se&#241;alaron como alteraciones cardiovasculares m&#225;s frecuentes la hipertrofia cardiaca, cardiomegalia, cardiomiopat&#237;a hipertr&#243;fica, particularmente el patr&#243;n de hipertrofia septal asim&#233;trica, disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo e hipertensi&#243;n arterial sist&#233;mica<sup>7-17</sup>. En Brasil, existe s&#243;lo el relato de un caso en el cual se describieron alteraciones card&#237;acas<sup>14</sup>.</p>
      <p>El objetivo de este trabajo fue determinar anormalidades cardiovasculares y metab&#243;licas en portadores de SBS, por medio de evaluaci&#243;n cl&#237;nica, ex&#225;menes bioqu&#237;micos, electrocardiograma (ECG) de reposo, radiograf&#237;a de t&#243;rax, ergometr&#237;a, ecocardiograma doppler y electrocardiograf&#237;a din&#225;mica de 24 horas (<italic>holter</italic>).</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>
        <bold>Individuos</bold>
      </p>
      <p>Se estudiaron 22 pacientes portadores de SBS, provenientes del Estado de Rio Grande do Norte (Brasil) atendidos en el Ambulatorio de Endocrinolog&#237;a y Metabolog&#237;a y de Cardiolog&#237;a del Hospital Universitario Onofre Lopes (HUOL) de la Universidad Federal de Rio Grande do Norte (UFRN). Cada paciente o su representante legal firm&#243; el Formulario de Consentimiento n&#186; 42/2003, debidamente aprobado por el Comit&#233; de &#201;tica en Investigaci&#243;n de la UFRN. Todos los ex&#225;menes se realizaron el mismo d&#237;a, y ning&#250;n paciente utilizaba ning&#250;n medicamento desde hac&#237;a por lo menos cinco d&#237;as.</p>
      <p>
        <bold>Par&#225;metros cl&#237;nicos</bold>
      </p>
      <p>Para cada participante se complet&#243; un protocolo que conten&#237;a datos personales, anamnesis y hallazgos del examen f&#237;sico general, endocrinol&#243;gico y cardiovascular. Todos los ex&#225;menes fueron realizados por m&#233;dicos especialistas.</p>
      <p>
        <bold>Evaluaci&#243;n antropom&#233;trica</bold>
      </p>
      <p>Las medidas de peso se obtuvieron en tres veces, mediante el uso de balanza digital (Balmark, S&#227;o Paulo, SP, Brasil), con capacidad para 160 kg y sensibilidad de 100 g. La circunferencia abdominal (CA) se midi&#243; sobre una l&#237;nea horizontal imaginaria que pasaba por el punto medio entre el borde inferior de la &#250;ltima costilla y la cresta il&#237;aca. El &#225;rea de la superficie corporal (ASC) se calcul&#243; por la ecuaci&#243;n de DuBois y DuBois<sup>18</sup>. Las medidas de peso y altura se utilizaron para el c&#225;lculo del &#237;ndice de masa corporal (IMC). Los ni&#241;os con IMC &gt; percentil 95 fueron consideradas obesas, y aquellas con IMC entre los percentiles 85 y 95, portadoras de sobrepeso<sup>19</sup>. Para los adultos, el IMC se consider&#243; normal entre 18,5-24,9 kg/m&#178;, sobrepeso entre 25,0-29,9 kg/m&#178; y obeso &gt; 30 kg/m&#178; <sup>20</sup>.</p>
      <p>
        <bold>Par&#225;metros bioqu&#237;micos</bold>
      </p>
      <p>Se recogieron 5 ml de sangre total, despu&#233;s de 12 h de ayuno. Se determinaron glucemia en ayunas, C-t, HDL-c y triglic&#233;ridos (TG). La lipoprote&#237;na de baja densidad (LDL-c) no fue calculada por volverse progresivamente menos exacta con el aumento de las concentraciones s&#233;ricas de TG y no ser utilizada para criterios de s&#237;ndrome metab&#243;lico (SM)<sup>20</sup>. Los an&#225;lisis se realizaron en un analizador bioqu&#237;mico (Modelo Chem Well, Palm City, FL, USA), usando reactivos espec&#237;ficos (Labtest, Minas Gerais, Brasil).</p>
      <p>
        <bold>Criterios y directrices</bold>
      </p>
      <p>Se utilizaron los criterios de normalidad definidos por la I Directriz de Prevenci&#243;n de la Aterosclerosis en la Infancia y la Adolescencia<sup>19</sup>, por la IV Directriz de Prevenci&#243;n de la Aterosclerosis de la Sociedad Brasile&#241;a de Cardiolog&#237;a<sup>20</sup> y por el Consenso Brasile&#241;o sobre Diabetes<sup>21</sup>. Los registros de informaciones, con relaci&#243;n a la resistencia a la insulina de cada individuo, se obtuvieron en los prontuarios del HUOL.</p>
      <p>Para evaluar los criterios de SM en ni&#241;os y adolescentes, se adoptaron los criterios de la NCEP/ATP III<sup>22</sup> modificado para la edad, siendo necesaria la presencia de por lo menos tres a cinco par&#225;metros: niveles de TG <underline>&gt;</underline> 110 mg/dl; HDL-c <underline>&lt;</underline> 40 mg/dl; circunferencia abdominal <underline>&gt;</underline> percentil 90, seg&#250;n sexo y edad; glucemia <underline>&gt;</underline> 110 mg/dl y presi&#243;n arterial sist&#243;lica o diast&#243;lica (PAS o PAD) <underline>&gt;</underline> percentil 90 seg&#250;n sexo, edad y estatura. Por otro lado, la NCEP/ATP III<sup>23</sup> preconiza que, para los adultos, el SM representa la combinaci&#243;n de por lo menos tres de los siguientes componentes: obesidad abdominal por medio de circunferencia abdominal (hombres &gt; 102 cm y mujeres &gt; 88 cm); TG <underline>&gt;</underline> 150 mg/dl: HDL-c para hombres &lt; 40 mg/dl y mujeres &lt; 50 mg/dl; presi&#243;n arterial <underline>&gt;</underline> 130 mmHg o <underline>&gt;</underline> 85 mmHg; y glucemia en ayunas <underline>&gt;</underline> 110 mg/dl. La presencia de <italic>diabetes mellitus</italic> tipo II no excluye el diagn&#243;stico de SM. Por su simplicidad y practicidad, &#233;sta es la definici&#243;n recomendada por la I Directriz Brasile&#241;a de Diagn&#243;stico y Tratamiento del S&#237;ndrome Metab&#243;lico<sup>24</sup>.</p>
      <p>
        <bold>Par&#225;metros hemodin&#225;micos</bold>
      </p>
      <p>Las presiones arteriales (PA) se midieron por el m&#233;todo indirecto, por medio de esfigmoman&#243;metro (Welch Allyn, Skaneateles Falls, NY, USA) graduado y calibrado de cero a 300 mmHg. Se verificaron tres medidas despu&#233;s de cinco minutos de reposo con el paciente en posici&#243;n sentada. Los procedimientos de las medidas y la clasificaci&#243;n de la presi&#243;n arterial se realizaron de acuerdo con <italic>The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents</italic> y el <italic>Seventh Report</italic> do <italic>Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</italic><sup>25,26</sup>. Los valores de la PA no fueron redondeados para d&#237;gitos terminados en cinco o cero.</p>
      <p>
        <bold>Electrocardiograma</bold>
      </p>
      <p>El electrocardiograma de reposo (ECG), realizado despu&#233;s de diez minutos de reposo, se registr&#243; en un aparato de electrocardiograf&#237;a (Cardioline Delta Plus, Cavareno, Trento, Italia) con 12 derivaciones. El registro gr&#225;fico se normaliz&#243; en la velocidad de 25 mm/s, y el aparato se calibr&#243; con amplitud de 1 mV, correspondiendo a 10 mm en el eje vertical<sup>27</sup>. La evaluaci&#243;n final fue realizada por dos cardi&#243;logos; en caso de discordancia, un tercer profesional determin&#243; el resultado final del examen.</p>
      <p>
        <bold>Radiograf&#237;a tor&#225;cica</bold>
      </p>
      <p>La radiograf&#237;a de t&#243;rax se realiz&#243; en un aparato (Emic, Modelo MKTE 500, S&#227;o Paulo, SP, Brasil) con sistema de procesamiento digital marca Agfa Cr 75.0 (Mortsel-Belgium) en inspiraci&#243;n m&#225;xima. Para los ni&#241;os que no pudieron permanecer en inspiraci&#243;n m&#225;xima, el examen se realiz&#243; con una distancia de 1m, generalmente en la proyecci&#243;n anteroposterior. En los adultos, la distancia fue del 1,75 a 2 m en proyecci&#243;n anteroposterior y perfil izquierdo. Usando tal t&#233;cnica se evaluaron el &#225;rea cardiaca, mediante el &#237;ndice cardiotor&#225;cico y la evaluaci&#243;n pleuropulmonar, y las c&#250;pulas diafragm&#225;ticas<sup>28</sup>.</p>
      <p>
        <bold>Ecocardiograma doppler</bold>
      </p>
      <p>Este examen realizado fue uni y bidimensional con <italic>doppler</italic> pulsado y continuo con mapeo de flujo en colores (Hewlett Packard, Modelo 2410 A-Ultrasound System, Andover-MA, USA). Se realizaron cinco medidas para cada variable estudiada, y para el an&#225;lisis se consider&#243; el valor promedio final. El aparato conten&#237;a transductores de 2.5 y 5.0 mHz, que permitieron la evaluaci&#243;n en el modo-M y en el bidimensional con <italic>doppler</italic> pulsado y continuo. Las im&#225;genes se obtuvieron siguiendo las recomendaciones de la <italic>American Society of Echocardiography</italic> (ASE)<sup>29,30</sup> a partir de cortes ecocardiogr&#225;ficos convencionales.</p>
      <p>Para el c&#225;lculo de la masa ventricular izquierda se adopt&#243; la f&#243;rmula recomendada por la ASE, corregida por la Convenci&#243;n de Penn<sup>31</sup>. El &#237;ndice de masa ventricular izquierda (IMVI) se calcul&#243; corrigiendo el valor de la masa (g) por la ASC (m&#178;). Se consider&#243; normal IMVE menor o igual a 95 g/m&#178; y 115g/m&#178; para mujeres y hombres, respectivamente<sup>32</sup>. El c&#225;lculo del espesor relativo de la pared (ERP) se obtuvo mediante al f&#243;rmula siguiente:</p>
      <p>ERP = (2 x EPPd) / DdV</p>
      <p>EPPd y DdV son el espesor diast&#243;lico de la pared posterior y el di&#225;metro diast&#243;lico final del ventr&#237;culo izquierdo, respectivamente.</p>
      <p>Los pacientes se clasificaron en cuatro grupos de geometr&#237;a card&#237;aca<sup>32</sup>:</p>
      <p>a) Geometr&#237;a normal = IMVE normal y ERP <underline>&lt;</underline> 0.42.</p>
      <p>b) Remodelaci&#243;n conc&#233;ntrica = IMVE normal y ERP &gt; 0.42.</p>
      <p>c) Hipertrofia conc&#233;ntrica = IMVE aumentada y ERP &gt; 0.42.</p>
      <p>d) Hipertrofia exc&#233;ntrica = IMVE aumentada y ERP <underline>&lt;</underline> 0.42.</p>
      <p>La fracci&#243;n de eyecci&#243;n (FE) se calcul&#243; por el m&#233;todo de Simpson a partir de un corte apical de cuatro c&#225;maras<sup>32</sup>. Fueron considerados normales valores <underline>&gt;</underline> 55%.</p>
      <p>Las evaluaciones de los flujos intracard&#237;acos siguieron las orientaciones del Consenso Canadiense y sirvieron para evaluar la funci&#243;n diast&#243;lica del ventr&#237;culo izquierdo<sup>33</sup>. Se obtuvieron las siguientes variables:</p>
      <p>a) Velocidad m&#225;xima de llenado ventricular r&#225;pido del flujo transmitral (pico de la onda E en m/s).</p>
      <p>b) Velocidad m&#225;xima de llenado tard&#237;o del flujo transmitral (pico de la onda A en m/s).</p>
      <p>c) Relaci&#243;n onda E / onda A.</p>
      <p>d) Tiempo de desaceleraci&#243;n de la onda E (TDE) del flujo transmitral en m/s correspondiente al intervalo de tiempo entre el pico de la onda E y su extrapolaci&#243;n para la l&#237;nea de base.</p>
      <p>e) Tiempo de relajaci&#243;n isovolum&#233;trica del ventr&#237;culo izquierdo (TRIV) en m/s correspondiente al intervalo de tiempo entre el final del flujo sist&#243;lico y el inicio del flujo transmitral.</p>
      <p>Las tres primeras variables se obtuvieron antes y durante la fase de presi&#243;n de la maniobra de Valsalva.</p>
      <p>
        <bold>Electrocardiograf&#237;a din&#225;mica de 24 horas (<italic>holter</italic>)</bold>
      </p>
      <p>Los pacientes se monitorearon durante 24 horas, utilizando un grabador (Cardioflash Digital Cardios, S&#227;o Paulo, SP, Brasil). La preparaci&#243;n, la realizaci&#243;n del examen, el an&#225;lisis y el laudo siguieron las orientaciones del <italic>ACC/AHA Guidelines for Ambulatory Eletrocardiography</italic><sup>34</sup>.</p>
      <p>
        <bold>Ergometr&#237;a</bold>
      </p>
      <p>Se realiz&#243; en una estera (IMBRAMED, Modelo Soft Move I, Porto Alegre, RS, Brasil). Los pacientes se prepararon para monitoreo de ECG continuo utilizando las derivaciones modificadas de Mason et al<sup>35</sup>. Se inici&#243; el examen utilizando el protocolo de Bruce<sup>36</sup>. Con la finalidad de evaluar las respuestas cl&#237;nicas, electrocardiogr&#225;ficas y hemodin&#225;micas, el examen sigui&#243; las orientaciones para resultados confiables, reproducibles y mensurables mencionadas en las II Directrices de la Sociedad Brasile&#241;a de Cardiolog&#237;a Sobre Ergometr&#237;a<sup>37</sup>.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>La comparaci&#243;n entre los dos subgrupos se analiz&#243; por el test de Mann-Whitney para datos num&#233;ricos y por el test exacto de Fisher para datos categ&#243;ricos (cualitativos). Los datos num&#233;ricos se determinaron en promedio y desviaci&#243;n est&#225;ndar, y los datos cualitativos se expresaron por medio de frecuencia (n) y porcentaje (%). Se utiliz&#243; el test no param&#233;trico de Mann-Whitney, pues las variables no presentaron distribuci&#243;n normal (distribuci&#243;n Gaussiana) debido a la falta de simetr&#237;a de la distribuci&#243;n, y principalmente debido al tama&#241;o de la muestra reducida en los subgrupos estudiados. El criterio de determinaci&#243;n de significancia adoptado fue el nivel de 5%. El an&#225;lisis estad&#237;stico se proceso con el <italic>software</italic> SAS 6.04 (SAS Institute, Inc., Cary, North Carolina, USA).</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>
        <bold>Individuos</bold>
      </p>
      <p>Las caracter&#237;sticas cl&#237;nicas de los 22 pacientes estudiados est&#225;n reunidas en la <xref ref-type="fig" rid="f1-body3">figura 1</xref> y en la <xref ref-type="table" rid="es_17t01-body3">tabla 1</xref>.</p>
      <p content-type="asset">
        <table-wrap id="es_17t01-body3">
          <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt01-es.jpg"/></table-wrap>
      </p>
      <fig id="f1-body3">
        <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gf01-es.jpg"/></fig>
      <p>
        <bold>Par&#225;metros cl&#237;nicos</bold>
      </p>
      <p>En la <xref ref-type="table" rid="es_17t01-body3">tabla 1</xref> tambi&#233;n se describen los par&#225;metros cl&#237;nicos. La historia familiar del SBS se identific&#243; en el 86,4% de los pacientes, con predominancia del sexo femenino (92,9%) por causa del mayor n&#250;mero. La <italic>diabetes mellitus</italic> tipo II ocurri&#243; en el 68,2% de los pacientes, siendo el 62,5% en el sexo masculino. El diagn&#243;stico de resistencia a la insulina y <italic>acanthosis nigricans</italic> fue demostrado en todos los pacientes. El SM ocurri&#243; en el 81,8% de los casos con prevalencia similar entre los sexos. La hepatomegalia ocurri&#243; en el 90,9% de los pacientes sin diferencia entre los sexos, y la esplenomegalia, en el 45,5%, predominantemente en el sexo femenino.</p>
      <p>
        <bold>Evaluaci&#243;n antropom&#233;trica</bold>
      </p>
      <p>Las caracter&#237;sticas antropom&#233;tricas de los 22 pacientes estudiados est&#225;n reunidas en la <xref ref-type="table" rid="es_17t01-body3">tabla 1</xref>. El promedio de edades fue de 22.4 &#177; 9.7 a&#241;os, sin diferencia estad&#237;stica entre los sexos. El promedio del peso fue de 56.6 &#177; 15.1 kg, siendo m&#225;s elevado en el sexo masculino (p = 0.003). El IMC present&#243; un promedio de 21.6 &#177; 3.3, siendo m&#225;s expresivo en el sexo masculino (p = 0.001). El promedio de la ASC fue de 1.58 &#177; 0.27, m&#225;s elevado en el sexo masculino (p = 0.004). La CA present&#243; un promedio de 82 &#177; 9.2, significativamente m&#225;s elevada en el sexo masculino (p = 0.011).</p>
      <p>
        <bold>Par&#225;metros bioqu&#237;micos</bold>
      </p>
      <p>La glucemia en ayunas se mantuvo en promedio elevado, 177,8 &#177; 84,4, sin diferencia significativa entre los sexos. El promedio del C-t fue de 175,4 &#177; 38,1, sin diferencia estad&#237;stica entre los sexos. El promedio del HDL-c fue 27,4 &#177; 7,7, m&#225;s elevado en el sexo femenino (p = 0.033). Los TG permanecieron elevados, 331,7 &#177; 286,4, aunque sin diferencia entre ambos sexos (<xref ref-type="table" rid="es_17t01-body3">tabla 1</xref>).</p>
      <p>
        <bold>Presi&#243;n arterial</bold>
      </p>
      <p>La frecuencia cardiaca basal tuvo un promedio de 91,6 &#177; 8,3, m&#225;s elevada en el sexo femenino (p = 036). La hipertensi&#243;n arterial sist&#233;mica (HAS) ocurri&#243; en el 50%, y la prehipertensi&#243;n, en el 27,3% de los pacientes con SBS (<xref ref-type="table" rid="es_17t01-body3">tabla 1</xref>). Los promedios de las PAS y PAD estaban aumentados en ambos sexos, aunque sin diferencia estad&#237;stica.</p>
      <p>
        <bold>Electrocardiograma</bold>
      </p>
      <p>Todos los pacientes con el SBS mostraron ritmo sinusal, el 18,2% presentaba hipertrofia ventricular izquierda (HVI), y el 3,6%, alteraci&#243;n de la repolarizaci&#243;n ventricular. Otras alteraciones fueron peque&#241;as (danos no mostrados).</p>
      <p>
        <bold>Radiograf&#237;a tor&#225;cica</bold>
      </p>
      <p>De los 22 pacientes con el SBS, el 95,5% presentaron radiograf&#237;a de t&#243;rax normal. S&#243;lo una mujer present&#243; aumento del &#225;rea cardiaca e inversi&#243;n del flujo pulmonar para los &#225;pices (datos no mostrados).</p>
      <p>
        <bold>Ecocardiograma Doppler</bold>
      </p>
      <p>En la <xref ref-type="table" rid="es_17t02-body3">tabla 2</xref>, los hallazgos del ecocardiograma Doppler se mostraban normales en el 40,9% de los pacientes, sin significancia estad&#237;stica entre los sexos. La regurgitaci&#243;n mitral leve apareci&#243; en el 27,3% de los pacientes con el SBS, con predominancia del sexo femenino. Se diagnosticaron calcificaci&#243;n de la v&#225;lvula a&#243;rtica en el 9,1% de los pacientes y presencia en el 4,5% con regurgitaci&#243;n a&#243;rtica leva s&#243;lo en los pacientes del sexo femenino. La hipertrofia conc&#233;ntrica del ventr&#237;culo izquierdo (HCVI) apareci&#243; en alrededor del 50% de los pacientes de ambos sexos, y la hipertrofia exc&#233;ntrica del ventr&#237;culo izquierdo, en el 4,5%, predominantemente en el sexo femenino. La geometr&#237;a normal del ventr&#237;culo izquierdo estuvo presente en el 45,5% de los casos estudiados, pr&#225;cticamente igual entre los sexos. Los patrones de la funci&#243;n diast&#243;lica evaluados por el flujo transmitral estaban dentro de la normalidad, antes y durante la fase de presi&#243;n de la maniobra de Valsalva (<xref ref-type="table" rid="es_17t02-body3">tabla 2</xref>). En lo que ata&#241;e a la evaluaci&#243;n de la funci&#243;n sist&#243;lica, vale destacar que la fracci&#243;n de eyecci&#243;n (Simpson) del VI tuvo un valor promedio del 67,3%, sin diferencia entre los sexos.</p>
      <p content-type="asset">
        <table-wrap id="es_17t02-body3">
          <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt02-es.jpg"/></table-wrap>
      </p>
      <p>La <xref ref-type="table" rid="es_17t03-body3">tabla 3</xref> relaciona la frecuencia y el porcentaje de HVI en el electrocardiograma y los par&#225;metros cl&#237;nicos con el ecocardiograma doppler (normal o anormal). La HVI en el ECG (30,8%), <italic>diabetes mellitus</italic> (76,9%), hepatomegalia (100%), esplenomegalia (61,5%) y HAS m&#225;s prehipertensi&#243;n (92,3%) estaban m&#225;s presentes en el ECO anormal.</p>
      <p content-type="asset">
        <table-wrap id="es_17t03-body3">
          <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt03-es.jpg"/></table-wrap>
      </p>
      <p>La <xref ref-type="table" rid="es_17t04-body3">tabla 4</xref> relaciona la frecuencia y el porcentaje de varios par&#225;metros cl&#237;nicos y HVI en el electrocardiograma con la hipertrofia conc&#233;ntrica del ventr&#237;culo izquierdo en el ecocardiograma. Entre los par&#225;metros electrocardiogr&#225;ficos, el 36,4% de la HVI se detectaron s&#243;lo en presencia de HCVI. Los par&#225;metros cl&#237;nicos m&#225;s frecuentes, tales como <italic>diabetes mellitus</italic> (72,7%), hepatomegalia (100%), esplenomegalia (63,6%) y HAS m&#225;s hipertensi&#243;n (90,9%), se observaron m&#225;s en presencia de la HCVI que en su ausencia.</p>
      <p content-type="asset">
        <table-wrap id="es_17t04-body3">
          <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt04-es.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Holter electrocardiograma</bold>
      </p>
      <p>La <xref ref-type="table" rid="es_17t05-body3">tabla 5</xref> muestra la asociaci&#243;n entre las arritmias verificadas en el <italic>holter</italic> y la incompetencia cronotr&#243;pica verificada en la ergometr&#237;a (TE) con relaci&#243;n a la HCVI observada en el ecocardiograma en 22 pacientes con SBS. Se observaron pacientes con <italic>holter</italic> normal con HCVI presente (18,2%) y ausente (36,4%), sin significancia estad&#237;stica entre ellos. Se detectaron igualmente extras&#237;stoles ventriculares en el 54,6% de los pacientes con HCVI presente y ausente. Pacientes con extras&#237;stoles supraventriculares presentaron el porcentaje del 81,8% asociado a la presencia de HCVI y el 54,6% a HCVI ausente. Se detect&#243; taquicardia supraventricular sostenida en el 27,3% de los pacientes con HCVI presente y 9,1% con HCVI ausente.</p>
      <p content-type="asset">
        <table-wrap id="es_17t05-body3">
          <graphic xlink:href="1678-4170-abc-94-01-0109-00017-gt05-es.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Ergometr&#237;a</bold>
      </p>
      <p>La incompetencia cronotr&#243;pica se observ&#243; en el TE en el 45,5% de los pacientes con HCVI presente y en el 63,6% con HCVI ausente, sin diferencia estad&#237;stica (<xref ref-type="table" rid="es_17t05-body3">tabla 5</xref>).</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>El SBS fue descrito en menos de 300 pacientes hasta el momento presente. La bibliograf&#237;a actual sugiere que s&#243;lo uno en cada cuatro casos es relatado, lo que permite una estimativa de la enfermedad de alrededor de uno en cada 10.000.000 habitantes<sup>3</sup>. El Estado de Rio Grande do Norte (Brasil) tiene una poblaci&#243;n estimada de 3.000.000 de habitantes. Por lo tanto, nuestro grupo constituye una muestra bastante significativa y la mayor casu&#237;stica de la bibliograf&#237;a mundial.</p>
      <p>La ocurrencia de anormalidades cardiovasculares y metab&#243;licas en portadores del SBS, actualmente, es poco discutida. En este estudio, la prevalencia de la consanguinidad paterna, <italic>diabetes mellitus</italic> tipo II, resistencia a la insulina, <italic>acanthosis nigricans</italic>, hepatomegalia, esplenomegalia, HDL-c diminuidos y TG aumentados fueron similares a los encontrados en la bibliograf&#237;a (<xref ref-type="table" rid="es_17t01-body3">tabla1</xref>)<sup>3,6,10,11,14,15,17</sup>.</p>
      <p>Un dato relevante de este estudio fue que, por primera vez, se identifico el SM en pacientes con SBS. &#201;ste se encontr&#243; en la gran mayor&#237;a de los pacientes, predominando en ambos sexos.&#201;ste se encontr&#243; en 18 pacientes (81,8%), siendo 11 (78,6%) del sexo femenino. De los siete ni&#241;os y adolescentes (31,81%) de este estudio, seis ten&#237;a criterios para SM, siendo cinco (71,42%) del sexo femenino y uno (14,28%) del sexo masculino. Los criterios m&#225;s prevalentes fueron bajo HDL-c (81,81%), hiperglucemia (77,27%), hipertrigliceridemia (63,63%) e hipertensi&#243;n arterial sist&#233;mica (50%). Con relaci&#243;n a la circunferencia abdominal, ning&#250;n paciente present&#243; aumento de esa variable. Los pacientes del sexo masculino presentaron la circunferencia abdominal m&#225;s elevada que los del sexo femenino, lo que implica mayores cuidados preventivos relacionados a las cardiopat&#237;as (<xref ref-type="table" rid="es_17t01-body3">tabla 1</xref>). Estos hallazgos fueron bastante significativos por la alta incidencia encontrada en el SBS y por ser representativos del aumento de la mortalidad general y de las complicaciones cardiovasculares<sup>24</sup>.</p>
      <p>Ning&#250;n paciente tuvo buen control de glucemia en ayunas, adem&#225;s de presentar HDL-c disminuido y TG elevados. Estos resultados fueron similares a los encontrados en la bibliograf&#237;a (<xref ref-type="table" rid="es_17t01-body3">tabla 1</xref>)<sup>3,6,10,11,14,15,17</sup>. La asociaci&#243;n de HDL-c bajo y elevaci&#243;n de TG aumentan enormemente los factores de riesgo para las enfermedades cardiovasculares<sup>24</sup>,</p>
      <p>Se observ&#243; hipertensi&#243;n arterial sist&#233;mica en el 50% de los pacientes. Estos resultados est&#225;n totalmente de acuerdo con otros autores que los encontraron en el 46,5% de los 13 casos cl&#237;nicos estudiados<sup>2,8,16</sup>. La prehipertensi&#243;n, no descrita anteriormente, se identific&#243; en el 27,3% de los pacientes (<xref ref-type="table" rid="es_17t01-body3">tabla 1</xref>). Esta clasificaci&#243;n de la prehipertensi&#243;n es particularmente importante para el tratamiento de pacientes con SM y <italic>diabetes mellitus</italic><sup>24,26</sup>.</p>
      <p>Otro dato relevante encontrado en este estudio tiene relaci&#243;n con los resultados obtenidos con el electrocardiograma y la radiograf&#237;a de t&#243;rax. Ambos par&#225;metros no fueron &#250;tiles para identificar la presencia de anormalidades card&#237;acas en el SBS, en particular la presencia de HVI. A diferencia de otros estudios que encontraron cardiomegalia como un hallazgo frecuente en la radiograf&#237;a de t&#243;rax<sup>7,8,11,13,16</sup>, s&#243;lo se observ&#243; un caso en el presente estudio (dato no mostrado). Por lo tanto, para identificar el compromiso cardiovascular, fue indispensable el estudio de ecocardiograma Doppler.</p>
      <p>Con relaci&#243;n a las anormalidades ecorcardiogr&#225;ficas de este estudio, se observ&#243; elevada prevalencia de compromiso card&#237;aco por medio de la presencia de hipertrofia conc&#233;ntrica del ventr&#237;culo izquierdo (50%), en ambos sexos, similar a los hallazgos de otros autores<sup>7,8,14,15,17</sup>. Por otro lado, no se encontr&#243; caso de cardiomiopat&#237;a hipertr&#243;fica, aunque la misma sea bastante citada en la bibliograf&#237;a como hallazgo frecuente<sup>6-8,11-13,15,38</sup>. Se observ&#243; un 4,5% de los pacientes con hipertrofia exc&#233;ntrica del ventr&#237;culo izquierdo. La regurgitaci&#243;n mitral leve se observ&#243; en seis pacientes con SBS. S&#243;lo un paciente presentaba hipocinesia global del ventr&#237;culo izquierdo y disfunci&#243;n sist&#243;lica (<xref ref-type="table" rid="es_17t02-body3">tabla 2</xref>).</p>
      <p>
        <bold>Resistencia a la insulina y cardiopat&#237;as</bold>
      </p>
      <p>La posibilidad de que la resistencia a la insulina ocasione hipertrofia del miocito es el probable eje histopatol&#243;gico, teniendo en vista la presencia de aumento de los di&#225;metros de las fibras y la ausencia de criterios de cardiomiopat&#237;a hipertr&#243;fica. En realidad, esta cardiomiopat&#237;a ocurre en pacientes con s&#237;ndrome de resistencia a la insulina por una acci&#243;n directa de la insulina en los receptores del factor de crecimiento similar a la insulina (IGF-1)<sup>10</sup>. La alta frecuencia de tal patolog&#237;a asociada a la hipertrofia conc&#233;ntrica en tales pacientes tambi&#233;n es relatada por Klar et al. <sup>12</sup> en 1993. En hallazgos de autopsia, las fibras estaban arregladas, sin dep&#243;sito de gluc&#243;geno e infiltraci&#243;n grasosa<sup>8,13</sup>. La cardiomiopat&#237;a hipertr&#243;fica vinculada a la <italic>diabetes mellitus</italic> se asocia, con frecuencia, a la dilataci&#243;n ventricular y a las alteraciones de las arterias coronarias<sup>13</sup>. En este estudio, se encontr&#243; s&#243;lo un paciente con aumento de los di&#225;metros internos del VI (hipertrofia exc&#233;ntrica) (<xref ref-type="table" rid="es_17t02-body3">tabla 2</xref>). La diferencia histol&#243;gica con la cardiomiopat&#237;a hipertr&#243;fica cl&#225;sica se realiza por la ausencia de desarreglo de las fibras en la hipertrofia asociada a lipodistrofia<sup>12,14</sup>.</p>
      <p>Divergiendo de otros estudios que identificaron elevada tasa de disfunci&#243;n diast&#243;lica por la evaluaci&#243;n del flujo transmitral<sup>7,8,13,14</sup>, no se encontr&#243; la disfunci&#243;n diast&#243;lica en nuestros pacientes, incluso despu&#233;s del empleo de la maniobra de Valsalva. Otro hallazgo discrepante de la bibliograf&#237;a<sup>8,11,15,38,39</sup> consisti&#243; en la presencia de disfunci&#243;n sist&#243;lica. S&#243;lo un paciente en este estudio present&#243; disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo. Una de las limitaciones de nuestro trabajo fue no utilizar el Doppler tisular, todav&#237;a no disponible en nuestro servicio.</p>
      <p>El <italic>holter</italic> identific&#243; elevada tasa de arritmia cardiaca en portadores del SBS. A pesar del bajo promedio de edades (22,4% &#177; 9.7) de estos pacientes, el 54,6% presentaron extras&#237;stoles ventriculares con HCVI presente, y otros 54,6%, con HCVI ausente (<xref ref-type="table" rid="es_17t05-body3">tabla 5</xref>). Con relaci&#243;n a la bibliograf&#237;a, existe s&#243;lo un relato de la paciente de cinco a&#241;os, que fue monitoreada por 24 horas y con <italic>holter</italic> normal<sup>38</sup>.</p>
      <p>Con relaci&#243;n a la ergometr&#237;a, se observ&#243; incompetencia cronotr&#243;pica en el 45,5% de los pacientes con HCVI presente y en el 63,6% en los pacientes con HCVI ausente (<xref ref-type="table" rid="es_17t05-body3">tabal 5</xref>). Este test fue normal para isquemia mioc&#225;rdica en los pacientes que alcanzaron la FC deseadas y en los que presentaron incompetencia cronotr&#243;pica. No hubo relaci&#243;n entre incompetencia cronotr&#243;pica y HCVI presente o ausente. La presencia de incompetencia cronotr&#243;pica es un predictor de aumento de la mortalidad cardiaca y enfermedad coronaria incipiente, por no alcanzar la FC deseada<sup>40</sup>. La gran relevancia de este hallazgo reside en el hecho de no haber trabajo en la bibliograf&#237;a que correlacione ergometr&#237;a e incompetencia cronotr&#243;pica en los portadores de este s&#237;ndrome.</p>
      <p>Finalmente, la muerte s&#250;bita se relata en pocos casos con alteraciones card&#237;acas. La relaci&#243;n de alteraciones card&#237;acas y dislipidemia se describe como causa de muerte s&#250;bita en el SBS<sup>8,12</sup>. Las alteraciones card&#237;acas aumentan con la edad<sup>7,8</sup>, lo que diverge en este estudio.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>Como conclusiones preliminares, los resultados obtenidos relevaron anormalidades cardiovasculares y metab&#243;licas con elevada prevalencia en pacientes j&#243;venes, asintom&#225;ticos y portadores de SBS. Estos hallazgos se&#241;alan la necesidad de seguimiento cardiol&#243;gico sistem&#225;tico y de medidas preventivas en este grupo de riesgo.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El MCT/FINEP/SINTEC, 01/2003, financi&#243; parcialmente el presente estudio.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de la tesis de doctorado de Ant&#244;nio Guedes do R&#234;go pela Universidad Federal de Rio Grande do Norte (UFRN).</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
